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Zusammenfassung 
Das Hepatitis B Virus (HBV) ist ein umhülltes hepatotropes Virus mit ausgeprägter Wirts-
spezifizität. Zur Infektion von Hepatozyten benötigt es den N-terminalen Teil des großen 
Hüllproteins (Large-surface protein, L-Protein), besonders die essentielle Domäne 
(Aminosäuren 9-15) und die N-terminale Myristoylierung.  
Die HBV-Infektion kann durch Zugabe von geringen Mengen an acylierten Peptiden, welche 
dem N-Terminus des L-Proteins entsprechen (HBV präS/2-48myristoyl), effizient inhibiert 
werden (IC50: 400 pmol). Hierfür sind wieder die Korrektheit der essentiellen Domäne und 
die N-terminale Fettsäure von Bedeutung. Werden diese Peptide Mäusen injiziert, so ist ein 
ausgeprägter Lebertropismus zu beobachten. Eine Mutation in der essentiellen Domäne 
führt zum Verlust des Lebertropismus, das entfernen der Acylierung verursacht eine rasche 
Ausscheidung des Peptids. Dies deutet auf eine Fettsäure-abhängige Bindung des Peptides 
an einen Serumfaktor hin. In dieser Arbeit wurden zunächst solche Faktoren identifiziert und 
die Interaktion charakterisiert; im zweiten Abschnitt wurde die Membranaktivität dieser 
Peptide untersucht. Der dritte Teil beschäftigt sich mit der hepadnaviralen Infektion 
verschiedener Spezies. 
Serum Albumin und Apolipoprotein A1 wurden als acylierungs-abhängige, sequenz-
unabhängige Bindepartner für HBV präS1-Peptide identifiziert. Das myristoylierte Peptid 
band Albumin mit geringer Affinität (KD =17µM), die Bindung an beide Faktoren stieg mit der 
Hydrophobizität des Peptids. Die Albuminbindung konnte in vivo bestätigt werden. Keiner 
der Faktoren hatte einen starken Einfluss auf die Bindung des Peptides an Hepatozyten, auf 
die HBV-Infektion oder auf die Infektionsinhibition. Diese Interaktionen stabilisieren also das 
Peptid im Serum, sie sind jedoch für weitere Schritte nicht relevant. 
Versuche, zelluläre Interaktionspartner für präS-peptide zu identifizieren, waren erfolglos.  
Im zweiten Teil dieser Arbeit wurde die Rolle der präS1-Domäne im viralen Zelleintritt 
untersucht. Da HBV ein umhülltes Virus ist, muss es während des Eintritts in die Wirtszelle 
sein Nukleokapsid freisetzen; die erste Transmembran-Domäne (TM-I), die den drei 
Oberflächenproteinen des Virus gemeinsam ist, wurde als virales Fusionspeptid beschrieben. 
Hier wurde die Membranaktivität des HBV präS1-Peptids analysiert. Es konnte gezeigt 
werden, dass dieses Peptid Modellmembranen in Abhängigkeit der essentiellen Domäne und 
der N-terminalen Acylierung destabilisiert. Koflotations-Versuche zeigten eine acylierungs-
abhängige Bindung an Liposomen. Dies deutet auf eine Rolle der präS1-Domäne im 
Zelleintritt hin. 
Der dritte Teil behandelt die Infektion von Hepatozyten verschiedener Spezies mit HBV, 
Hepatitis Delta Virus 2, ein Viroid, welches vermutlich den gleichen Zelleintrittsmechanismus 
verwendet wie HBV und Waldmurmeltier-HDV (Woodchuck-HDV, WHDV); letzteres ist ein 
Hepatitis Delta Virus, welches die Oberflächenproteine des Woodchuck-Hepatitis Virus trägt. 
Hierfür wurden primäre Hepatozyten von Ratte, Kaninchen, Hamster und Meerschweinchen 
isoliert und mit HBV, HDV oder WHDV infiziert. Ratten-Hepatozyten konnten weder mit HBV 
noch mit HDV infiziert werden. Kaninchen-Hepatozyten waren suszeptibel für HDV, jedoch 
nicht für HBV. Sowohl in Hamster- als auch in Meerschweinchen-Hepatozyten war eine HBV-
Infektion, jedoch keine HDV-Infektion detektierbar. Alle getesteten Hepatozyten waren 
suszeptibel für eine WHDV-Infektion. 
Diese Daten weisen darauf hin, dass der HBV-Rezeptor auch in anderen Spezies vorhanden 
ist. Die Restriktion der verschiedenen Infektionnen findet vermutlich an einem späteren 
Schritt statt und ist für HDV und HBV verschieden.  
Summary 
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Summary 
 
Hepatitis B Virus (HBV) is an enveloped, hepatotropic virus with a restricted host range. 
Infection of hepatocytes has been shown to require the N-terminal part of the large 
envelope protein (L-protein); intactness of the essential site (amino acids 9-15) is crucial, the 
N-terminal myristoylation is mandatory.  
HBV infection is efficiently inhibited by lipopeptides corresponding to the N-terminus of the 
L-protein (HBV preS/2-48myristoyl). Equally requiring the essential site and the N-terminal 
acylation, these peptides prevent HBV infection already at picomolar concentrations (IC50: 
400 pmol).  
These features are also important for a marked liver tropism that is observed when preS-
peptides are injected into mice. While a non-acylated peptide gets rapidly excreted from the 
body, a mutant acylated peptide is retained but loses its liver specificity, arguing for an 
acylation-dependent serum factor binding. 
In this work, serum factor binding and membrane activity of these peptides were analyzed; a 
third part addressed hepadnaviral infection of different species.  
First, serum albumin and apolipoprotein A1 have been identified as acylation-dependent, 
sequence-independent interaction partners for HBV preS-derived lipopeptides. The 
myristoylated peptide bound albumin with relatively low affinity (KD =17µM), binding to both 
serum factors was found to increase with hydrophobicity. Albumin binding was confirmed in 
vivo. None of the identified factors had a marked effect on peptide-binding to hepatocytes, 
HBV infection or infection inhibition. It was therefore concluded that these interactions 
stabilize the peptide in the serum but are not required for further steps. Attempts to identify 
protein binding partners for preS-peptides on hepatocytes were unsuccessful. 
In the second part, the focus turned towards viral entry. Being an enveloped virus, HBV has 
to release its nucleocapsid during viral entry; the first transmembrane-domain (TM-I), 
common to the three surface proteins, has been proposed as viral fusion peptide. Here, a 
possible role of the N-terminal part of the L-protein during this step was studied by analyzing 
the membrane activity of preS-derived peptides. They could be shown to destabilize model 
membranes depending again on the essential site and the acylation; coflotation assays 
demonstrated acylation-dependent association to liposomes. This indicates a possible 
involvement of the L-protein N-terminus in viral fusion. 
In the third part, it was assessed whether other hepatocytes from small animals belonging to 
different orders show susceptibility to HBV, to hepatitis delta virus 2, a viroid thought to 
share a common entry pathway with HBV, or to woodchuck hepatitis delta virus (WHDV), an 
HDV-virus containing the envelope proteins from woodchuck hepatitis virus. Primary 
hepatocytes from rat, rabbit, hamster and guinea pig were therefore isolated and infected 
with HBV, HDV or WHDV. Rat hepatocytes could not be infected, neither with HBV nor with 
HDV. Rabbit hepatocytes showed susceptibility to HDV, but not to HBV. In both hamster and 
guinea pig hepatocytes, HBV infection but no HDV infection was observed. All primary 
hepatocytes were susceptible to WHDV.  
These findings indicate that the receptor for HBV is also present in other species; restriction 
of infection probably occurs at a post-entry step and affects HDV and HBV separately. 
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1. Introduction 
1.1 Viral Hepatitis B 
An infection with the Hepatitis B Virus (HBV) is one of the most frequent causes for an 
inflammation of the liver (hepatitis) and represents a major health issue. Today, about two 
billion people carry markers of an HBV infection, 350 million are currently chronically 
infected 3. 
The term hepatitis B dates back to 1947, when MacCallum described jaundice development 
after measles-vaccinations with inoculates from measles-patients 4. He suggested the 
differentiation between epidemic infectious hepatitis, termed hepatitis A, and a 
"homologous serum hepatitis", termed hepatitis B. The causative agent for the latter was 
not identified until the mid sixties. Blumberg and coworkers described an antigen in the 
serum of an aboriginal patient that reacted with antibodies from a hemophilia patient and 
was later found to be involved in the development of hepatitis 5. Prince and colleagues 
performed immunofluorescence staining on liver sections 6 and immunodiffusion tests in 
serum of multiply transfused patients 7. Both times, they detected an antigen that they 
brought into connection with viral hepatitis B.  
The consequences of an HBV-infection range from transient hepatitis to chronic infection. 
The latter can lead to liver cirrhosis, liver failure or hepatocellular carcinoma (HCC), which 
account for HBV being among the ten most important causes of death worldwide. HCC, a 
non-HBV specific disease, causes 300.000 to 500.000 deaths every year. More than 4 million 
acute cases of HBV are registered annually, and one quarter of the infected die of chronic 
active hepatitis, cirrhosis or primary liver cancer 3. 
High endemic areas for HBV are South East Asia, the Pacific region (without Japan, Australia 
and New Zealand), sub-Saharan Africa, the Amazon basin, parts of the Middle East, central 
Asia and some countries of Eastern Europe (fig. 1.1). In these regions, which are inhabited by 
about 45% of the world population, 70-90% of all people get infected with HBV before 
reaching the age of 40; 20% are chronically HBV-infected.  
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In northern America, Western and Northern Europe, Australia and parts of South America, 
HBV occurs only sporadically. Less than 2% of the population are chronically infected, the 
infection rate is at ~20% 3. With 0,4 - 0,8% chronically infected patients and 5 - 8% infection 
rate, Germany can be classified as low endemic country (fig.1.1).  
Fig.1.1 HBV seroprevalence in the world. This world map shows prevalence of hepatitis B Virus surface antigen 
(HBsAg) which is commonly used as marker for HBV infection. Countries with high prevalence are marked in 
dark blue, countries with intermediate prevalence in blue and countries with low prevalence in light blue. 
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1.1.1 Transmission routes of HBV 
HBV is transmitted parenteral via blood, blood products and other body fluids, such as sudor 
or lacrimal fluid. While the human body is the only reservoir of the virus, HBV stays 
infectious outside of the body for a certain time; yet, the most common ways of 
transmission are direct contact with injured skin or mucosa. In highly endemic areas, 
infection occurs usually perinatally (during birth) or in early childhood. In low and medium 
endemic regions, this route is rare; horizontal transfer of the virus by unprotected sexual 
contact or use of contaminated needles for drug consumption is observed more frequently. 
Medical personnel that often has contact with virus-containing blood is also at an increased 
risk of infection 9.  
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1.1.2 Epidemiology and pathogenesis 
After entering the host, HBV reaches the liver via the blood system where it infects 
hepatocytes, the liver parenchymal cells. Here, replication of the virus is not causing cell 
death; as there is no immediate immune answer, 70-100% of the hepatocytes usually get 
infected 10.  
It is only when a strong T-cell answer, directed against HBV-derived peptides being 
presented on the surface of infected hepatocytes, causes secretion of cytokines (e.g., TNF-
α), free radicals and proteases that hepatocytes undergo cell death 11.  
65% of all infections in adults proceed without apparent symptoms; 35% develop the 
immunopathologically caused acute hepatitis whose most prominent symptom is the icterus 
(jaundice) 12. 1% of all acute infections develop into a fulminant hepatitis. If liver 
transplantation does not take place, this leads to rapid decay of the liver and to the patient’s 
death. In 90 - 95% of infections, however, the disease passes with complete elimination of 
the virus from the liver, without causing any liver damage. Viral antigens are no longer 
detectable, antibodies against the HBV S-antigen (HBsAg) conferring life-long immunity are 
found in the serum. The remaining 5 - 10% of infected patients develop a chronic HBV 
infection that progresses with or without symptoms. The virus continuously replicates, 
causing a constant immune reaction against hepatocytes without clearance of infection 11. 
Up to 90% of perinatal infections become chronic due to the immature immune system in 
infants. 
Chronic infection is defined by persistence of the viral small surface antigen (HBsAg) in the 
serum of infected patients for more than six months 12. It is thought to be caused by a weak 
or absent immune reaction. Patients with a chronic HBV infection have a 100 fold increased 
risk of developing liver cancer; 10-25% die of HCC or liver cirrhosis 12. It is assumed that 60-
80% of primary liver cancer are caused by HBV 13. 
1.1.3 Prophylaxis and therapy 
Since 1981, a safe and efficient vaccine from purified HBsAg is available. Being formerly 
purified from plasma of HBV infected patients, it is nowadays produced mainly by usage of 
genetically modified yeast cells. Vaccination with this HBsAg confers immunity against HBV 
for approximately 10 years 12.  
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For HBV infected patients, there is no drug that reliably eliminates the virus. All therapies 
target suppression of viral replication, aiming to avoid liver failure by cirrhosis or HCC. 
Besides immunomodulatory treatment with interferon α, nucleoside- and nucleotide 
analogues such as Lamivudine, Adefovir, Entecavir, Telbivudine, Clevudine and Tenofovir are 
employed 14. Treatment with these drugs, however, favors the emergence of escape 
mutations in the HBV DNA polymerase, leading to formation of resistant viruses. For 
example, 80% of all patients under Lamivudine-treatment develop resistant mutants within 
4 years 15.  
Several new nucleoside/nucleotide analogues with improved antiviral action are currently 
being developed, and the inhibition of viral replication by targeting other viral proteins is 
under investigation 14. 
1.2 Hepadnaviridae 
The HBV virus is the prototype of the Hepadnaviridae, a family of small enveloped viruses 
with a partially double stranded DNA-genome that can cause a sometimes chronic form of 
liver inflammation (Hepatotropic DNA Viruses). This family can be divided into two genera: 
orthohepadnaviruses infect mammals while avihepadnaviruses target birds. Both genera 
have certain features in common: 
 A 3 - 3,3kb relaxed circular DNA (rcDNA) 
 A virus-associated polymerase that can fill the gap in the partially double stranded 
genome 
 The production of a large excess of subviral particles 
 A marked host specificity with strong liver tropism. 
The family of orthohepadnaviruses includes several viruses isolated from different primates, 
squirrels or woodchucks that show differing sequence-homology with HBV. Isolates from 
primates are very close to human HBV and are therefore considered as genotypes (table 
1.1).  
Avihepadnaviruses (table 1.2) share only ~40% of their sequence with HBV. Their genomes 
are smaller and code for only two surface proteins (orthohepadnaviruses: three surface 
proteins). Also, they do not code for the X-protein, a non-structural protein with unclear 
function. Given the rather easy access to peking ducks, whose hepatocytes are susceptible to 
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duck hepatitis B virus (DHBV) infection, these animals have been frequently used as animal 
model in HBV research.  
 
Table 1.1.: Representative members of the orthohepadnaviruses (from: 
16
) Gorilla HBV shows only 5% 
divergence from chimpanzee HBV, these viruses are therefore classified as one genotype.  
Virus host abbreviation 
Hepatitis B Virus human 
Homo sapiens 
HBV 
Chimpanzee-Hepatitis B Virus Chimpanzee 
Pan troglodytes 
HBVcpz 
Gibbon-Hepatitis B Virus White-handed Gibbon 
Hylobates lar 
HBVgbn 
Orang Utan-Hepatitis B Virus Orang Utan 
Pongo pygmaeus 
HBVoru 
Gorilla Hepatitis B Virus Gorilla 
Gorilla gorilla 
HBVcpz 
Woolly Monkey Hepatitis B Virus Woolly Monkey 
Lagothrix lagotricha 
WMHBV 
Woodchuck Hepatitis B Virus Woodchuck 
Marmota monax 
WHV 
Ground squirrel Hepatitis B Virus Ground squirrel 
Spermophilus beecheyi 
GSHV 
Arctic squirrel Hepatitis B Virus Arctic squirrel 
Spermophilus parryi 
ASHV 
 
Table 1.2.: Representative members of the avihepadnaviruses (from: 
16
) 
Virus host abbreviation 
Duck Hepatitis B Virus Peking Duck 
Anas domesticus 
DHBV 
Grey Teal Hepatitis B Virus Grey Teal 
Anas gibberifrons gracilis 
GTHBV 
Heron Hepatitis B Virus Heron 
Ardea cinerea 
HHBV 
Maned Duck Hepatitis B Virus Maned Duck 
Chenonetta jubata 
MDHBV 
Ross Goose Hepatitis B Virus Ross Goose 
Anser rossi 
RGHV 
Snow goose Hepatitis B Virus Snow Goose 
Anser caerulescens 
SGHBV 
Stork Hepatitis B Virus Stork 
Ciconia ciconia 
STHBV 
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1.2.1 HBV genotypes 
Due to a high replication rate and the high error rate of the viral reverse transcriptase, the 
hepatitis B virus is capable of quickly adapting to changes in environmental conditions. This 
led to the emergence of the eight different genotypes HBV-A to HBV-H (criteria: sequence 
homology < 92%). Furthermore, these genotypes can be further divided into subgenotypes 
that differ in their geographic prevalence. These are defined by two pairs of determinants of 
the HBsAg that behave mainly allelic und mutually exclude each other: d,y and r,w.  
 
Table 1.3.: HBV-Genotypes. Given are length of genome, differences in the ORFs and geographic prevalence. 
(from 
16
).  
Genotype Length of the 
genome (in bp) 
ORF-differences Geographic prevalence 
A 3221 Insertion of aa 153 and 154 in HBc Africa 
Europe 
B 3215  Asia 
C 3215  Asia, Australia 
D 3182 Deletion of  aa 1-11 in preS1 Mongolia, Europe, India, Southern 
Africa, Australia 
E 3212 Deletion of aa 11 in preS1 Central Africa 
F 3215  Southern and central America 
G 3248 Insertion of 12 aa in HBc 
Deletion of aa 11 in preS1 
Central America 
H 3215  Central America 
 
1.2.2 Viral particles 
The infectious agent of HBV is a spherical particle with a diameter of 42 - 47 nm, called 
Dane-Particle after its discoverer 17 (fig. 1.2). It contains an icosahedral capsid built of 240 
units of the core-protein (also called Hepatitis B core Antigen, HBcAg). This capsid has a 
diameter of 22-25 nm and contains the 3,2 kb-viral genome and the viral polymerase. It is 
enveloped by a membrane that consists mainly of viral envelope proteins and to ~25% of 
host-derived lipids (mainly phospholipids, cholesteryl-esters and triglycerides) 18. The small 
envelope protein (S-protein) is the main component; due to its antigenicity, it is also called 
Hepatitis B surface Antigen. The membrane also contains the middle protein (M-protein), 
whose function is unknown, and the large protein (L-protein), which is responsible for virus 
envelopment during morphogenesis 19 and for receptor binding during virus entry 20. 
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Cells infected with HBV produce not only Dane-particles but also subviral particles (SVPs). 
SVPs consist of non infectious empty membrane material that does not contain capsids (fig. 
1.2). They exist either as spherical particles with a diameter of ~22 nm or as filamentous 
particles of 22nm in diameter, reaching up to 200nm in length. SVPs are found in the serum 
of infected patients in a 104-106 – fold excess over the Dane-particles. The distribution of the 
surface proteins differs between the three viral particles; while Dane-particles have a S:M:L-
ratio of 4:1:1, this ratio is 100:5:1 in spherical SVPs. Filamentous particles have a slightly 
larger amount of L-protein compared to spherical SVPs.  
 
1.2.3 The viral genome 
Inside the capsid, the viral DNA is found as partially double stranded, ~3200 base pairs (bp) 
relaxed circular DNA (rcDNA). The negative strand is of one unit length (3100-3300 bp, 
differing by subtype); it has the terminal protein 21 bound 5´-terminally. The positive strand 
is shorter (1700-2800 nt) and has a 17-19 nt oligoribonucleotide on its 5´-end. Both strands 
contain direct repeats (DR) of 11 nucleotides; the one on the negative strand is called DR1, 
the other DR2 (fig. 1.3). 
Fig. 1.3: Organization of the HBV-genome. Inner black 
circle: rcDNA, positive strand. Outer black circle: rcDNA, 
negative strand with associated reverse transcriptase 
(triangle). positions of the direct repeats 1 and 2 are 
indicated (white circles). On the inside, positions of the 
open reading frames (ORFs) are given, coding for either 
surface proteins (preS1/ preS2/ S), the viral polymerase (P) 
the precore/core (preC/C) or the X-protein (X). The outer 
blue circles depict either subgenomic RNAs with their 
different initiation points (white triangles) and polyA-tails 
on the 3´-end or the genomic RNA with its encapsidation 
signal ε. From: 
22
 
 
 
 
Fig.1.2. Left panel: Electron 
micrograph of negative-stained HBV-
particles. Right panel: Schematic 
representation of the composition 
of Dane-particles, spherical and 
filamentous subviral particles. S, M, 
L: small, middle and large surface 
protein, respectively. RT: reverse 
transcriptase. TP: terminal protein. 
preS1/2: N-terminal extensions of 
the surface proteins. Courtesy of S. 
Seitz. 
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The HBV genome is tightly organized; every nucleotide is in a coding region, over 50% of the 
sequence are part of an open reading frame (ORF). It contains a total of four ORFs (tab. 1.4): 
 The preS-S (presurface-surface) ORF encodes the three viral surface proteins; it has three 
in frame-start codons that allow a differential initiation of translation. 
 The preCore/ Core ORF codes for the Hepatitis B core-antigen (HBcAg) and the Hepatitis 
B early-Antigen (HBeAg), a soluble factor with unknown function. Initiation of translation 
on an internal AUG leads to the production of the 21 kDa core protein; initiation on an 
upstream start codon causes synthesis of the 24 kDa precore protein, the e-antigen. The 
precore-sequence contains a signal-sequence directing the nascent protein to the 
secretory pathway. During its passage through the Golgi-apparatus, it is cleaved by 
cellular proteases, giving rise to the 16 kDa HBeAg that is secreted into the blood stream.  
 The viral polymerase is responsible for DNA-synthesis and for packaging of the viral 
genome into newly formed capsids; it is encoded by the polymerase-ORF (P-ORF).  
 The X-ORF contains the sequence for the X-protein, a factor that is able to modulate the 
host cell signal transduction as well as the gene expression of viral and host-genes. Its 
exact function is unknown, but it has been shown to be necessary for viral replication. 
 
Table 1.4: HBV proteins. Name, molecular weight, modifications and function are indicated.  
Protein Name Molecular weight and 
modifications 
Function 
HBsAg S-protein 24 kD 
27 kD    glycosylated 
surface protein 
induction of neutralizing antibodies 
formation of particles 
preS2-HBsAg M-protein 33 kD 
36 kD    glycosylated  
surface protein 
binding to Serum albumin 
preS1-HBsAg L-protein 39 kD    acylated 
42 kD    acylated,     
glycosylated 
surface protein 
receptor binding 
capsid binding in morphogenesis 
HBcAg Core-protein 22 kD    phosphorylated capsid protein 
binding the genome at envelopment 
HBeAg e-antigen 16 kD secreted protein, correlates with HBV 
replication 
HBx X-protein 17 kD transactivator for viral and cellular 
promotors 
exact function unknown 
P polymerase 90 kD DNA-and  RNA-dependent Polymerase 
(reverse Transcriptase), RNAse H, terminal 
protein for initiation of replication 
 
 
Introduction 
 
 
9 
1.2.4 The viral surface proteins 
The membrane of HBV contains three type II transmembrane glycoproteins that are all 
encoded by a single ORF (fig. 1.4): the small (S), the middle (M) and the large (L) surface 
protein 23. The S-protein is the main membrane component of all HBV particles. It has a 
length of 226 aa and a glycosylation site on Asn146; since this site is modified in only a part 
of all S-proteins, there is an unglycosylated (24kDa) and a glycosylated form (27kDa) 24. It 
possesses four transmembrane domains and forms the membrane anchor of all three 
surface proteins (fig. 1.4).  
Initiation of transcription 165 nucleotides upstream leads to the synthesis of the M-protein. 
It is characterized by 55 additional amino acids (aa) on the N-terminus. This so-called preS2-
domain is partially glycosylated on Asn4 and has a molecular weight of 33 kDa and 36 kDa, 
respectively. The M-protein is N-terminally acylated and accounts for 5-15% of all HBsAg 25.  
The start codon for the L-protein lies 489 nucleotides upstream of the S-start codon; 
translation of the corresponding mRNA gives rise to a 334-345 aa protein (depending on the 
genotype). The L-protein is therefore characterized by its preS1-domain of 108-119 aa and 
carries a N-terminal signal for myristoylation on Gly2 26. The attachment of this C14 fatty 
acid is performed cotranslationally by cellular N-myristyl transferases 27. It has been shown 
to play no role during viral assembly, yet it is indispensable for viral infectivity 28. The L-
protein, which accounts for 1-2% of all HBV surface proteins, is also partially glycosylated in 
the S-domain and occurs therefore in two isoforms, p39 and gp42.  
 
 
 
 
 
 
 
 
 
Fig. 1.4: schematic representation of the domain structure of the Large (L), the middle (M) and the small (S) 
HBV surface proteins. Red: S domain. Orange: preS2-domain. pink: preS1-domain. yellow: transmembrane 
domains.   : glycosylation.         : myristoylation. Numbers indicate amino acids. p:protein gp: glycoprotein; ggp: 
double glycosylated protein. Courtesy of S. Seitz. 
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1.2.5 Topology of the surface proteins 
Since the HBV surface proteins are membrane proteins, they are synthesized and inserted 
cotranslationally on the membrane of the endoplasmatic reticulum (ER), where they adopt 
their complex membrane topology 29 (fig. 1.5).  
The insertion of the S-protein into the ER-membrane is initiated by a N-terminal signal 
sequence (aa 8-22), which will not be cleaved by a host protease but composes the first 
transmembrane domain (TM-I). A second signal at aa 80-98 leads to the translocation of the 
downstream polypeptide through the ER-membrane and into the ER-lumen; the upstream 
sequence stays in the cytosol, the signal itself becomes the transmembrane domain II (TM-II) 
30. The C-terminal 57 hydrophobic aa of the S-protein also get embedded into the ER-
membrane and form the TM-III and TM-IV (fig. 1.5). The C-terminus of the S-protein faces 
the ER-lumen, aa 23-79 form a cytosolic loop, aa 99-169 face again the ER-lumen and form a 
large loop, the so called a-determinant, which carries the main epitope of the HBV surface 
antigen (HBsAg) (fig. 1.5). After particle secretion, cytosolic parts will be located on the 
inside of the particle, while ER-luminal parts will be exposed on the outside of the particle.  
Fig.1.5: Schematic representation of the transmembrane topology of the three HBV glycoproteins. Red: S-
domain. Orange: preS2-domain. pink: preS1-domain. yellow: transmembrane domains.   : glycosylation.         : 
myristoylation. The N-terminus of the S-protein and the preS2-domain of the M-protein are directed towards 
the ER-lumen, the preS-domain of the L-protein adopts a dual topology: when oriented towards the inside of 
the particle, it binds the viral capsid, when oriented towards the outside, it mediates receptor recognition. 
Courtesy of S. Seitz.  
 
The M-protein is synthesized in the same manner as the S-protein; thus, the preS2 domain is 
positioned towards the ER-lumen and on the particle surface after secretion 31. 
The L-protein has to fulfill a dual role, its topology is therefore subjected to changes. Since 
HBV has no defined matrix protein, this function is fulfilled by the preS-domain of the L-
protein. During its synthesis, the preS-domain is oriented towards the cytosol. Here, it 
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ensures binding of the capsid and therefore formation of enveloped viral particles 32. After 
translation, 50% of the preS-domains get translocated to the outside if the viral particle (fig. 
1.5).33;34. Recent data indicate a maturation process of viral particles involving a 
translocation of all L-proteins ( S. Seitz, unpublished data). This translocation is necessary for 
receptor interaction, which has also been mapped to the preS1-domain 20. The time point 
and the mechanism of this preS-translocation are under debate.  
1.2.6 HBV entry 
1.2.6.1 Animal models and cell culture systems 
The first steps of a viral infection are often composed of a low-affinity, energy independent 
and reversible interaction of the virus with a cell surface structure, followed by a high-
affinity binding to a specific receptor that mediates endocytosis. Thereafter, enveloped 
viruses have to uncoat their capsid by fusion of the viral membrane with a cellular 
membrane (plasma membrane or endosomal membrane). These initial events are only 
poorly understood in the case of HBV, since until recently, there have been only few in vivo 
or in vitro systems available. Due to the restricted host range of HBV, only primates (mainly 
chimpanzees) have been used 35. These use of these animals, however, has been abandoned 
for ethical and financial reasons. The discovery that the tree shrew Tupaia belangeri can be 
infected with HBV 36;37 led to the first small animal model for HBV. Primary human 
hepatocytes (PHH) have been employed as an in vitro model, but these cells are obtainable 
only by surgical excision of liver parts from patients. Furthermore, PHH are problematic in 
cultivation, cannot be passaged and show high variance in their susceptibility.  
Only recently,  Gripon and colleagues described the hepatoma cell line HepaRG that is 
derived from a female patient suffering from chronic Hepatitis C Virus infection 38. These 
cells can be passaged and, when treated with dimethylsulfoxid (DMSO), undergo a 
differentiation process that leads to susceptibility for HBV infection. 
1.2.6.2 Early steps of HBV infection 
Infection of hepatocytes is initiated by low affinity binding of the virus to cell surface 
Heparan Sulfate Proteoglycans (HSPGs) in a L-protein dependent manner 39. This initial 
attachment step is followed by binding to an unknown cellular receptor and endocytosis. 
While the M-protein was shown to play no role in HBV infection40, the S- and the L-protein 
are necessary for this step. The part of preS being essential for HBV infection was shown to 
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be in the preS1-sequence (aa 3-77); here, only a small deletion of aa 78-87 is tolerated 20. 
Further deletions of the preS2-sequence do not influence viral infectivity 41. The 
myristoylation at the N-terminus of the preS1 was shown to be necessary for infectivity 42; 28, 
yet its exact function is unknown.  
On the cellular side, no receptor molecule for HBV has reliably been identified. Several 
molecules have so far been proposed, among which Interleukin 6 43, the human squamous 
cell carcinoma antigen 1 (SCCA1) 44 or the asialoglycoprotein receptor 45. Direct proof as an 
entry receptor has been given for none of these molecules.  
The cellular receptor for the duck hepatitis B Virus (DHBV) has been found to be the duck 
caboxypeptidase D (dCPD) 46. This is a trans-Golgi network protein that binds the primary 
binding sequence of the dHBV L-protein, aa 86-115. This part of the dHBV L-protein is a 
largely unstructured domain that binds at first with relatively low affinity to the dCPD, 
passing into a stronger interaction that is thought to finally mediate the fusion between the 
viral and the cellular membrane 46; 47. For human HBV, however, this mechanism seems to 
play no role, since the human version of carboxypeptidase D does not bind the HBV L-
protein.  
1.2.7 The viral replication cycle 
After receptor-mediated endocytosis, the viral capsid gets uncoated and is transported 
towards the nucleus where it delivers the viral genome. The core protein possesses a nuclear 
localization signal which facilitates the nuclear import 48. The release of the viral genome 
occurs within the nuclear pore, where the capsid dissociates 49. Once in the nucleus, the 
positive strand of the HBV DNA gets completed and its ends get ligated, leading to the 
formation of episomal covalently closed circular DNA (cccDNA) 50. 
The cccDNA now serves as a template for the formation of viral RNAs by the cellular RNA 
polymerase II, which transcribes the cccDNA into three subgenomic RNAs (two for the 
surface proteins, one for the X-protein) and one pregenomic RNA (pgRNA). All formed RNAs 
have the same polyadenylation signal close to the core-ORF. While the subgenomic RNAs 
serve only as mRNAs, the pgRNA has two functions: it is the template for the synthesis of the 
viral DNA and also the mRNA for the translation of the preCore-, the Core-protein and the 
viral polymerase.  
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Following the export of the viral RNAs into the cytoplasm, the membrane proteins are 
synthesized on the ER-membrane and the Core-protein, the e-antigen and the viral 
polymerase are synthesized in the cytoplasm. The pgRNA has a hairpin secondary structure 
called ε close to its 5´-end; this is recognized and covalently bound by the N-terminus of the 
viral polymerase 51; 52. The ε-structure serves as primer for the synthesis of the first four 
nucleotides of the negative strand 53. After initiation, the entire complex is transferred to 
homologous sequences on the 3´-end and serves now as primer for the synthesis of the 
negative strand. Simultaneously, the RNA-template gets degraded by the RNAse H activity 
on the C-terminus of the polymerase 54. At the end of the negative strand synthesis, a 
oligoribonucleotide remains on the 3´-end; it now serves as primer for the synthesis of the 
positive strand 55. 
The ε-signal of the pgRNA also functions as a packaging signal; therefore, it is already during 
reverse transcription that the complex of pgRNA and polymerase gets bound by core protein 
and packaged into immature capsids. Maturation of the capsid before the end of positive 
strand synthesis leads to the characteristic partially double stranded genome.  
The mature capsid can now pursue one of two ways: it either gets reimported into the 
nucleus, where the formation of new cccDNA increases this pool until 20 or more of these 
molecules are present and serve as templates for transcription 56. This way is predominant 
during early time points of the infection and allows accumulation of cccDNA. When the 
amount of surface proteins increases, the capsids bind preferentially to the N-terminus of 
the L-protein and get translocated through the ER-membrane 57; 58. After passage through 
the Golgi-complex, the virions get secreted into the blood.  
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Fig. 1.6: The HBV replication cycle. HBV enters hepatocytes by binding to an yet unknown receptor molecule 
(1). After endocytosis (2), fusion of the viral membrane with a cellular membrane (3) leads to release of the 
nucleocapsid (4) that then gets transported to the nucleus (5). The viral genome is then released into the 
nucleus (6) where the positive strand gets completed and ligated (7); cccDNA is formed. Transcription of 
cccDNA by RNA-Pol-II (8) leads to formation of the mRNAs for surface proteins (9) and formation of the 
pregenomic RNA (pgRNA), which serves as mRNA for the core-protein (10) and as template for reverse 
transcription into viral DNA. Immature genomes get packaged into assembling nucleocapsids. These either get 
reimported into the nucleus or get enveloped at the ER-membrane where translation of viral surface proteins 
takes place (14). These viral particles then leave the cells by passage through the ER and the Golgi (15).  
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1.3. HBV preS1-derived lipopeptides as entry inhibitors 
In 2005, Gripon and colleagues described lipopeptides derived from the L-protein preS1 N-
terminus as potent inhibitors of HBV entry. Using HepaRG cells and primary human 
hepatocytes, they demonstrated that the first 47 amino acids (aa 2-48) are essential for 
infection inhibition and that the N-terminal acylation strongly enhances the inhibitory effect, 
postulating an IC50 of 8nM 
59. These findings were later confirmed on primary hepatocytes 
from Tupaia belangeri 60 and in in vivo studies on immunnodeficient whose livers were 
repopulated with primary Tupaia belangeri hepatocytes. In these in vivo studies from 
Petersen and colleagues, the ability to inhibit infection could be shown to be sequence 
dependent; it was furthermore observed that these peptides exhibit a strong liver tropism 
that is independent of the cells´ susceptibility to HBV, since accumulation of the preS-
peptides was also observed in murine hepatocytes 61. 
More detailed analysis of the peptides regarding their sequence requirements for infection 
inhibition and liver tropism in mice 62; 63) revealed that both features strongly correlate. An 
intact amino acid sequence, concerning especially the essential site of aa 9-15, and the 
presence of a N-terminal acylation are both required for infection inhibition and for liver 
tropism (fig. 1.7). Mutations in the essential site, such as a G12E-mutation or a replacement 
of aa 11 and 13 by their respective D-enantiomer strongly reduced the HBV infection 
inhibition and abolished liver tropism, leading to equal distribution of these peptides 
throughout the body of the mice. A non-acylated version of the peptide was excreted from 
the body within four hours after injection (fig. 1.7).  
 
 
Fig. 1.7: Liver tropism of 
131
I-labeled HBV preS1-derived peptides in mice. NMRI mice were intravenously 
injected with radioactively labeled HBV preS1-derived peptides. A myristoylated wildtype version (left panel), a 
stearoylated peptide carrying the G12E-mutation (middle panel) or a non-acylated wildtype version (right 
panel). At the indicated time points, organs were harvested and radioactivity was measured in a γ-counter. 
Three animals were used for each time point.(Data from:
63
).  
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Further studies of the preS1-peptide binding to different primary hepatocytes and HepaRG 
cells showed that this binding takes place on a variety of primary hepatocytes (such as 
rabbit, rat or dog hepatocytes, fig. 1.8), is dependent on the differentiation state of the cell 
and is most likely mediated by a cytoskeleton-linked proteinacious component of the plasma 
membrane 64.  
 
Fig. 1.8: Binding of FITC-labeled HBV preS-derived peptides to primary hepatocytes from mouse and rat. 
Primary hepatocytes from mouse (PMH) and rat (PRH), cultured on cover slips, were incubated without or with 
200 nM fluorescein-isothiocyanate (FITC)-labeled acylated wildtype, acylated mutant or non-acylated wildtype 
peptide, respectively, washed and fixed. Plasma membrane-bound fluorescence was documented by spinning 
disk confocal microscopy with a 600x magnification. Autofluorescence is shown on the left (without peptide). 
Modified from A. Meier 
64
.  
 
1.4. Membrane fusion 
The fusion of two membranes is a tightly regulated process during which two lipid bilayers 
merge into one. This generally requires the presence of specialized proteins that bring these 
two membranes into close proximity and cause a local disturbance in the bilayers. This 
process plays a role in cell-cell communication (e.g., in neuronal exocytosis), intracellular 
transport (e.g., ER/golgi-shutteling), protein degradation by lysosomes, and is necessary for 
cell entry of enveloped viruses 65. It is generally believed to occur via a hemifusion 
intermediate where, after having been brought into close contact, the adjacent monolayers 
fuse first, followed by fusion of the distant monolayers (fig. 1.9). 
p
ri
m
ar
y 
m
o
u
se
 
h
e
p
at
o
cy
te
s 
p
ri
m
ar
y 
ra
t 
h
e
p
at
o
cy
te
s 
no peptide 
acylated wildtype 
peptide 
acylated mutant 
peptide 
non-acylated 
wildtype peptide 
Introduction 
 
 
17 
 
Fig. 1.9: Model of membrane fusion via the hemifusion intermediate. An example for a vesicle containing a 
soluble cargo fusing with a target membrane is depicted. After protein-mediated tethering (1), the vesicle is 
bound closely to the target membrane, an eventual priming of the fusion machinery takes place (2). Fusion is 
initiated by induction of membrane curvature (3). This leads to fusion of the adjacent outer membrane bilayers, 
the so-called hemifusion (4). Fusion of the inner bilayers induces full formation of the fusion pore (5), followed 
by full collapse and release of the cargo (6). (taken from: 
65
). 
1.4.1. Viral membrane fusion 
In order to enter cells, viruses bind cell surface proteins and induce membrane fusion by 
specialized viral fusion proteins. In this process, insertion of viral fusion peptides into target 
membranes usually catalyzes the fusion process by destabilizing the membrane and reducing 
the required activation energy. This happens either at neutral pH at the plasma membrane 
or after endocytosis.  
Viral fusion proteins, typically type I transmembrane proteins, are today divided into two 
classes 66. Type I viral fusion proteins are characterized by an alpha-helical core structure. 
They are usually synthesized as single chain precursors that assemble into trimers and 
undergo proteolytic cleavage by host cell proteases soon after their synthesis, leading to 
formation of a metastable state. Upon activation during viral entry, refolding of the protein 
into a trimeric coiled coil takes place and exposes the viral fusion peptide that will be 
inserted into the target membrane. The Influenza haemagglutinin (HA) protein is a typical 
example for a type I fusion protein. The envelope proteins of flaviviruses are known 
examples of type II fusion proteins. These proteins, consisting most often of β-sheets, do not 
require proteolytic activation, but possess an internal fusion peptide. Often, the cleavage of 
another surface protein is required for the activation of the fusion protein itself 66. During 
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the last years, a third class of viral fusion proteins has been proposed 67. Their fusion 
proteins consist of five distinct domains and trimerize through their ectodomains, forming 
rod-like molecules of varying size. Fusion peptides of class III fusion proteins are less 
conserved than in the other two classes.  
The influenza HA is synthesized as fusion-incompetent precursor (HA0) which is 
proteolytically cleaved into two subunits68;69: HA1 stays covalently attached to the 
transmembrane subdomain, HA2 is attached by a disulfide bond 70. In the prefusion state, 
HA forms homotrimers that have their three fusion peptides buried within the molecule. 
Upon binding of HA1 to its receptor, the sialic acid, the virus is endocytosed 71. In the low pH 
of the endosome, the HA2 fusion peptide is exposed and inserted into one layer of the target 
membrane, where it induces curvature and bends it towards the viral membrane 72 (fig. 
1.10). During this process, one part of the HA2 changes from an extended loop conformation 
into a coiled coil, propeling the fusion peptide towards the host cell membrane. It is believed 
that the prefusogenic structure is primed for a conformational change that leads to fusion. It 
could be demonstrated that the HA2 fusion peptide adopts a boomerang-shaped structure 
that inserts it into the lipid bilayer 73 and lies in the target membrane inclined by ~45° 74 (fig. 
1.10). The C-terminal domain of HA2 then folds back and forms a hairpin-like structure, 
thereby bringing the two membranes into close proximity. This induces curvature of the 
target membrane , the so-called nipple-formation, that will ultimately lead to membrane 
fusion.  
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Fig. 1.10: The Influenza virus fusion pore formation. After endocytosis (a), the low pH of the endosome leads 
to a conformational change in the HA-protein and to exposure of the viral fusion peptide that gets inserted into 
the endosomal membrane (b). The C-terminal domain of the HA-protein then folds back into a coiled coil (c) 
which induces curvature in the viral and in the endosomal membrane. This induces stress on the membranes 
which is released by fusion of the outer membranes (d), leading to the hemifusion state (e). Ultimately, the 
inner membranes fuse, the fusion pore opens (f). Taken from 
75
. 
 
1.4.2 Viral fusion peptides 
The fusion peptide, which is often rich in hydrophobic and glycine residues, always interacts 
with the host cell membrane at an early stage of membrane fusion. Inclination is a feature 
often observed for viral fusion peptides that are therefore sometimes referred to as "tilted 
peptides". These are generally short protein fragments with an asymmetric distribution of 
hydrophobic residues that leads to inclined insertion into a membrane. In 1988, the fusion 
peptide of Newcastle disease virus was shown to have a 55° inclination in a phospholipid 
monolayer 76. These membrane destabilizing peptides have several common features, such 
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as an overall hydrophobicity, a prevalence of small residues and show a gradient of 
hydrophobicity when helical.  
Some viral fusion peptides do not insert themselves into the target membrane but merely 
associate with the surface of the membrane by interaction with phospholipids. This has been 
described for peptides from the HIV gp41 N-terminus 77 that is thought to interact with 
negatively charged phospholipids and thereby gets inserted laterally into the host cell 
membrane, inducing curvature.  
Interaction with phospholipids can induce formation of structures in viral proteins; Galdiero 
and coworkers reported such behaviour for Herpes simplex virus type I glycoprotein-derived 
peptides performing circular dichroism measurements of liposomes 78. An extensive study 
on structural properties of viral fusion properties compared peptides from several viruses, 
including Influenza 79, HIV (class I) or tick-borne encephalitis virus 79 and also compared 
these to cellular fusion proteins such as syntaxin 80. Formation of secondary structures upon 
exposure to trifluoroethanol (TFE), which is known to stabilize secondary structures, was 
studied by circular dichroism spectroscopy. for all studied peptides, an increase in secondary 
structure was observed when TFE-concentrations increased; the need for structural 
flexibility in fusion peptides was proposed. Hofmann and coworkers designed unnatural 
peptides with fusogenic activity. They postulated that the ratio of α-helix promoting leucine 
to β-sheet promoting valine is crucial, and that secondary-structure destabilizing prolines 
and glycines in the hydrophobic core act as enhancers 81. 
1.4.3 Membrane fusion by hepatitis B viruses 
HBV does not encode a classical fusion protein requiring proteolytic cleavage for successful 
entry. Lu and coworkers described HBV infection of otherwise non-susceptible HepG2 cells 
after protease treatment of viral particles, claiming the exposure of a fusion sequence 
between the pres2- and the S-domain 82.  
For the duck hepatitis B virus (DHBV), the first transmembrane domain (TM-I) of the large 
surface protein has been proposed as fusion peptide that is necessary for DHBV entry 83, 84. It 
is thought that acidification leads to exposure of the TM-I on the viral surface, a step which 
would be required for membrane fusion.  
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Interaction of HBV preS-domains with phospholipid vesicles has been described 85; In these 
studies, however, recombinantly expressed preS-peptides without N-terminal acylations and 
no mutant controls were used. These results therefore should be interpreted with caution. 
1.5. Hepatitis Delta Virus 
1.5.1. History and pathogenesis 
Four decades ago, Rizzetto and coworkers described a new antigen in hepatocytes and 
serum of chronically HBV infected patients 86, using immunofluorescence. Assuming that this 
new antigen was another antigen produced by the HBV infection, it was termed Hepatitis 
Delta Antigen (HDAg). It was not until 1980 that this antigen was assigned to a single strand 
RNA-genome virus, then called Hepatitis Delta Virus 2; 87. HDV was then classified into a new 
genus, the deltaviridae.  
Today, 8 HDV genotypes are known; genotypes 2-7 are specific for certain geographic areas 
88. HDV can either co-infect with HBV 89, leading to ~5% chronicity, whereas superinfection 
leads to a chronic infection in up to 80% of all cases. Interestingly, HBV replication is usually 
suppressed in chronically HDV infected patients 90.  
HDV infection usually induces severe hepatitis within 37 weeks post infection, fulminant 
hepatitis being recorded more often than in HBV infection alone. The resulting massive 
necrosis of hepatocytes leads to liver failure and death in 80% of all cases, liver 
transplantation often being the only remedy.  
Coding only for the delta antigen, HDV depends on the surface proteins of HBV for the 
production of new viral particles and can therefore spread only in the livers of patients 
infected with HBV; it is therefore termed a satellite virus. 
1.5.2. Morphology and viral proteins 
HDV forms spherical, 36-43 nm particles containing a ribonucleic core-like structure with a 
diameter of 19 nm. A lipid shell containing the HBV surface proteins envelops one genomic 
RNA of 1700 nt which is complexed with ~70 molecules of the large and small Delta antigen 
(fg. 1.11) (HDLAg and HDSAg, respectively). These are synthesized from one ORF and differ 
only by 19 additional amino acids on the C-terminus of the HDLAg 91. 
The Delta Antigen consists of dimers of an antiparallel coiled coil structure leading to 
oligomerisation into octamers and thereby form ringlike structures of 50 Å diameter; it is not 
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exposed on the viral surface (fig. 1.11). HDAg contains a nuclear localization signal (NLS) that 
allows targeting of the ribonucleoprotein (RNP) to the nucleus 92. A domain comprising 
amino acids 35-65 allows binding to the nucleolus-protein nucleolin 93. Three arginine-rich 
domains are thought to be responsible for binding to the HDV RNA 94. Furthermore, HDLAg 
contains a nuclear export signal (NES) 95 and a farnisoylation motif on its C-terminus 96. The 
viral envelope contains all three HBV surface proteins in a L:M:S-ratio of 95:5:1, being more 
similar to subviral spheres than to HBV particles (fig. 1.11).  
 
 
 
 
 
Fig.1.11: Schematic representation of the HDV particle, the Delta antigens and their functional domains. 
A: The HDV particle. RNP: ribonucleoprotein. HDSAg: small hepatitis delta antigen. HDLAg: large hepatitis delta 
antigen. HBV-L/M/S: large, middle and small hepatitis B virus surface protein, respectively.  
B: Electron micrograph of affinity purified HDV-particles. From: Gudima et al., 2007. 
C: The large (HDLAg) and small (HDSAg) HDV proteins and their functional domains. NLS: nuclear localization 
signal. NES: nuclear export signal.  
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Introduction 
 
 
23 
1.5.3 HDV entry 
As for HBV, the entry process of HDV into hepatocytes is largely unknown. There are, 
however, many similarities between HDV and HBV entry, pointing towards a common 
mechanism. It has been shown that, as for HBV, the L-protein is crucial for HDV infectivity 97, 
especially the residues 1-75 98, requiring the presence of the N-terminal myristoylation 99. 
Strongly hinting towards a common entry receptor is the fact that HDV infection, as well, can 
be inhibited by acylated preS1-derived lipopeptides 100. In contrast to HBV, HDV does not 
require the glycosylation of the surface proteins for efficient infection 101. As for HBV, the 
antigenic loop (AGL) in the S-domain is also needed, since virions containing deletions in this 
domain have been shown to lose infectivity 102; its function in viral entry has been reported 
to be independent from that of the preS1-domain 103.  
1.5.4 The HDV genome and its replication 
HDV particles contain a circular, negative single strand RNA 104 of 1672-1679 nt in length 105; 
106. It shows 74% internal base pairing and therefore folds as unbranched, double stranded 
rod like structure 104. The nucleotides 680-780 form a ribozyme domain that allows 
autocleavage and ligation 107; 108; 104 and a putative promotor site for the HDAg RNA. 
Replication of HDV (fig. 1.12) takes place without DNA intermediates and leads to the 
occurrence of three forms of RNA: in an infected cell, the genome, the antigenome, and the 
mRNA for the Delta-Antigen are present in a ratio of ~ 500:50:1 104. This is performed 
exclusively by the RNA-Polymerase II 109. 
Following entry, the HDV genome is localized to the nucleus where RNA-Pol-II transcribes it 
into the 800 nt mRNA that encodes the HDSAg. The small antigen is required for replication 
of the genome by binding to RNA-Pol-II and inhibiting binding of the negative elongation 
factor (NELF). Replication itself occurs via the rolling circle mechanism. This leads to the 
formation of the multiple concatemers of the antigenome, which are autocatalytically 
cleaved by its ribozyme activity, ligated by cellular ligases and thus form a new template for 
synthesis of the genome 110; 111. This is then either packaged into viral particles or serves 
again as template for antigenome synthesis.  
Early in infection, formation of HDSAg is predominant, ensuring a highly active replication of 
the genome. The HDLAg is synthesized only later, when the enzyme adenosine deaminase 
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acting on RNA-1 (ADAR-1) edits the antigenome post-transcriptionally, leading to 
deamination of Adenosine 105 into Inosine 112. Thereby, the stop-codon UAG becomes an 
UIG, now coding for tryptophane, allowing synthesis of the large antigen. HDLAg then acts as 
dominant negative inhibitor on the replication, a property which is enhanced by the N-
teminal isoprenylation 113. When no HBsAg is present in the cell, a nuclear localization signal 
(NLS, aa 66-75) localizes HDLAg and HDSAg to the nucleus; only in the presence of HBsAg do 
they relocalize to the cytoplasm, where the isoprenylated HDLAg mediates binding to the 
HBV surface proteins 114; 115.  
 
 
 
Fig. 1.12: The HDV replication cycle. Genomic RNA (1) is transcribed into mRNA for HDSAg (2), which is then 
translated into HDsAg (3). HDsAg then cooperates with RNA-Pol-II to form complementary antigenomic RNA (4) 
that serves as template for the formation of new genomic RNA. The action of ADAR-1 on this antigenomic RNA 
leads to the formation of edited antigenomic RNA (5). This is again translated into genomic RNA (6) which is 
transcribed by RNA-Pol-II into mRNA for HDLAg (7). From this mRNA, HDLAg is translated which represses 
replication of the genome and is therefore important for morphogenesis of HDV virions. Modified after 
116
. 
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1.6. Transport of fatty acid esters and fatty acids in the blood 
1.6.1. Lipoproteins 
The human body requires substantial amounts of lipids, especially phospholipids, for 
membrane synthesis, cholesterol for membrane modification and as raw material for certain 
hormones as well as fats as energy reservoir. These molecules are either synthesized by the 
liver or enter the body as dietary fat through the gut. Independent of their origin, 
redistribution of fats and fatty acids in the body is necessary in order to meet every organs´ 
needs. Since these molecules are very hydrophobic but are transported in the blood - a 
hydrophilic environment - special transport mechanisms are required. This task is fulfilled by 
lipoproteins which are large aggregates of triglycerides, phospholipids and cholesterol 
wrapped in a layer of specialized proteins, the so called apolipoproteins. Blood contains a 
variety of lipoproteins that are responsible for different transport ways and vary in their 
plasma levels according to the dietary status of a person. Since lipoproteins differ in their 
content of lipids and fats, they show characteristic differences in their density which led to 
their classification. An overview of lipoproteins in human plasma is given in table 1.5.  
 
Table 1.5: Main lipoproteins in plasma and their characteristics. from 
117
 
Lipoprotein Chylomicron Very low density 
lipoprotein 
118
 
Low density 
lipoprotein 
118
 
High density 
lipoprotein (HDL) 
apolipoproteins apoA-IV, apoB-48, 
apoC-II, apoC-III, 
apoE 
apoB-100. apoC-I, 
apoC-II, apoC-III, 
apoE 
apoB-100 apoA-I, apoA-II, 
apoA-IV, apoC-I-III, 
apoD, apoE 
transport way intestine to liver liver to periphery periphery periphery to liver 
density (g/ml) <1,0006 0,95-1,0006 1,0006-1,063 1,063-1,210 
transported fats triglycerides, 
cholesterol 
triglycerides, 
phospholipids, 
cholesterol 
phospholipids, 
cholesterol 
cholesterol 
 
Triacylglycerides are the main form of storage fat in the body, where they are stocked in 
adipocytes. When hormones signalize the need for these fats, they are mobilized from the 
adipose tissue, the fatty acid ester bonds are enzymatically dissolved and free fatty acids are 
released. Those enter into the bloodstream, where they bind to the abundant transporter 
molecule serum albumin and get transported to the site of need (heart, sceletal muscles, 
cortex of the kidneys). 
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1.6.2 Serum albumin as transporter molecule and its role in hepatic uptake of fatty acids 
Serum albumin is the most abundant protein in plasma; this 62 kDa protein is found at a 
concentration of 42 mg/ml (640 µM) and thus constitutes around 50% of all serum proteins.  
Its fatty acid binding was described first by Kendall in 1941 who observed that after 
cristallization, albumin still showed a yellowish colour. He ascribed this to the association of 
fatty acids 119. It is known today that albumin binds 0,1-2 mol of fatty acids (up to 10 in 
certain disease states) per mol HSA in a non-covalent way 120; 121 and thus assures their 
transport in the blood. Albumin has a half life of ~20 days and is produced in the liver of a 
normal healthy adult at a rate of ~15 grams per day. 
Human serum albumin (HSA) is a 585 amino acid protein that comprises three homologous 
domains (I-III) consisting of two subdomains (A and B) each, the whole protein being 
stabilized by a total of 17 disulfide bonds. Albumin has been shown to undergo structural 
changes upon alterations in pH, calcium concentration and fatty acid binding and is thought 
to be stabilized by binding to fatty acids. In 1975, Sudlow and colleagues reported two 
distinct binding sites on HSA that were identified by displacement studies on fluorescently 
labeled drugs 122. These binding sites have since then been termed Sudlow site I and II; three 
subdomains for site I have been described more recently 123. Site I is relatively large since 
large molecules such as bilirubin bind here and several reports of two different compounds 
binding to this site simultaneously have been made 124. Due to its broad ligand spectrum, 
this site is thought to be relatively flexible in its structure.  
Sudlow site II is probably smaller since it does not bind larger substances; it is not subdivided 
into more domains; binding is often strongly stereoselective, typical ligands are aromatic 
carboxylic acids 125.  
Fatty acids are bound to HSA with a relatively high affinity, varying with their length; 
dissociation constants (KD) of 460 nM for the interaction between human Serum Albumin 
(HSA) and myristic acid 120 and 14 nM for the HSA-stearic acid (C18) binding 126 have been 
reported. Binding of fatty acids leads to structural changes in the HSA molecule; binding to 
Sudlow Site I has been shown to lead to a rearrangement of the hydrogen bond network in 
this site, increasing the volume of this pocket and altering its polarity by opening up a 
solvent channel in this site 127. A recent study on the binding of phospholipids has reported 
KD values of, e.g., ~5 µM for binding of Lysophosphatidylethanolamine 
128.Many endogenous 
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substances such as bilirubin, hemin or thyroxine bind to different sites on HSA; these are 
mainly acidic, lipophilic substances getting transported in the blood in this complex 129. 
Svenson et al. performed a study on the binding of short cationic antimicrobial peptides 
using isothermal titration calorimetry and reported a KD in the range of 4-22 µM 
130.  
 
Fig. 1.13: Crystal structure of HSA and its ligand binding sites. Ligands are depicted in space filling 
representation; oxygen atoms are colored red; all other atoms in fatty acids or endogenous ligands are colored 
dark grey, light grey and orange, respectively. IB- IIIA: subdomains A and B of the homologous domains i-III. FA: 
fatty acid binding site. black: natural ligands. orange: drugs binding to the respective sites. from: 
127
. 
1.6.3 Drug transport by HSA 
Apart from natural ligands, albumin is an important interaction partner for different drugs, 
strongly affecting their adsorption, metabolism, elimination and solubility. This is mainly the 
case for acidic or electronegative compounds such as Diazepam or Ibuprofen, usually binding 
at subdomains IIA or IIIA (fig. 1.13) 131. While this binding often helps solubilizing those 
molecules, drugs that bind with high affinity to HSA (>95% bound) usually show a slower 
distribution, require higher doses and may not be efficiently eliminated from the body.  
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Drugs bind mainly to Sudlow site I or Sudlow site II. In site I, they occupy partially 
overlapping binding compartments; for some cases, interactions between drugs and 
endogenous ligands, especially fatty acids, have been reported 132, competition or 
cooperation between both playing a role. 
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2. Material and Methods 
2.1 Material 
2.1.1 Cell culture 
eucaryotic cell lines  
HepaRG Human hepatoma cell line, isolated from a patient with HCC and 
chronic HCV infection (Gripon 2002) 
HepAD 38 derived from a human hepatoma cell line (HepG2); stably 
transfected with a plasmid that contains HBV-cDNA under control of 
a tetracycline-regulated promotor 
 
cell culture media  
HepaRG cultivating medium: Williams Medium E, 10% FCS (heat inactivated), 
50U/ml penicillin, 50µg/ml streptomycin, 50µM hydrocortisone-
hemisuccinate, 5µg/ml insulin 
differentiating medium: as cultivating medium; addition of 2% 
DMSO 
HepAD38 cultivating medium: DMEM/F-12, 10% FCS (not heat inactivated), 
50U/ml penicillin, 50µg/ml streptomycin, 400µg/ml G418, 50µM 
Hydrocortisone-hemisuccinate, 5µg/ml Insulin, 0,3µg/ml Tetracyclin 
Medium for virus-production: as cultivating medium, without 
tetracyclin 
primary hepatocytes  isolation medium: Williams Medium E without additives 
cultivating medium (until 4h after isolation): Williams Medium E, 
10% FCS, 50U/ml penicillin, 50µg/ml streptomycin, 73µg/ml L-
glutamin 
cultivating medium (4h after isolation): Williams Medium E, 50U/ml 
penicillin, 50µg/ml streptomycin, 73µg/ml L-glutamin 
 
2.1.2  Equipment and consumables 
Rotors  
SW-28-Rotor  Beckman 
SW-60 Rotor  Beckman 
TH 660-Rotor  Sorvall 
TH 641-Rotor  Sorvall 
TLA 120-Rotor  Beckman 
   
Chromatography system 
Component name manufacturer 
Äkta Purifier 10  GE Healthcare, Sweden 
pH/ conductivity sensor pH/C 900 GE Healthcare, Sweden 
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UV-monitor UV 900 GE Healthcare, Sweden 
system pump P 900 GE Healthcare, Sweden 
sample pump P 960 GE Healthcare, Sweden 
fraction collector Frac 950 GE Healthcare, Sweden 
control unit CU 950 GE Healthcare, Sweden 
injection valve INV 907 GE Healthcare, Sweden 
position valve PV 908 GE Healthcare, Sweden 
Mixer M925 GE Healthcare, Sweden 
Unicorn 5.1 Software  GE Healthcare, Sweden 
   
consumables 
Product  Manufacturer 
cannulae 22G, 0,55×25mm B. Braun 
cannulae 27G, 0,4×19mm B. Braun 
Cell culture bottle 75cm2 Corning 
Cell culture dish 100mm Corning 
Cell culture 12/24 well plate  Corning 
Cell strainer 100nm Beckton Dickinson 
Centrifuge tubes, quickseal 8×35mm, polyallomer Beckman 
Centrifuge tubes 25×89mm, polyallomer Beckman 
Centrifuge tubes 14×95mm, polyclear Seton 
Chromatography paper, 3MM Chr  Whatman 
Corning Polystyrol Cellstack   Corning 
Cotton swabs Sterile packed Noba 
Coverslips, ø 18mm  Marienfeld GmbH 
Diaper inlay Molinea Hartmann 
dissecting instruments  Aesculap /others 
Filter 0,2 µm (for syringes)  Sartorius 
Filter 0,45 µm (for syringes)  Roth 
Filtrating membrane Nitrocellulose 
0,45µm 
 Millipore 
folded filter ø 185mm  Sartorius 
Glass bottles  250ml, 500ml, 1000ml 
2000ml 
Schott 
Glass graduated cylinder 50ml, 100ml, 250 ml, 
1000ml, 2000ml 
Brand 
Glass micropipettes 2µl-100µl Drummond scientific 
Glass pipettes 5ml, 10ml, 20ml, 25ml Hirschmann 
Glass tubes for liposome 
preparation 
12 ml volume Schott Duran 
Microwell 96 well plate Luminunc, white VWR 
Nitrocellulose membrane, 0,45µm  Schleicher & Schuell 
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Nylon membrane, positively charged  Roche Applied Science 
Parafilm  American Can 
Company 
Pasteur pipettes, 230mm  WU Mainz 
Petri dish, 100mm×15mm  Greiner Bio-One 
Perfusion tubing Silicone, ø 2mm Amersham 
Perfusion tubing Silicone, ø 7,5mm Masterflex 
Pipet 2-20µl, 20-200µl, 200-
1000µl 
HTL lab solutions 
Pipet tips, with filter  Starlab 
Pipet tips, without filter  Starlab 
Pipet boy Accujet Pro Brand 
Quick seal centrifuge tubes  Beckman 
Reaction tubes  0,5ml, 1,5ml, 2ml Sarstedt 
Reaction tubes  15ml, 50ml Greiner Bio one 
sample tubes for AxSYM 2ml Sarsted 
Scalpels   B. Braun 
Serologic Pipets 5ml, 10ml, 25ml Corning 
Serum collection tubes 8ml serum monovette Sarstedt  
Syringes 1ml, 5ml, 10ml; luer-lock B. Braun 
Syringes 50ml, luer-lock Becton-Dickinson 
three-way stopcocks luer-Lock, 10cm Becton Dickinson 
Vacuum-filter, Bottle-top, 0,45µm  Corning 
Venous catheter 22G, 0,9mm×25mm B. Braun 
Venous catheter 24G, 0,5mm×19mm Abbocath 
 
Equipment type manufacturer 
95°C-Oven  Heraeus 
Autoclave EL V 5050 Tuttnauer Systec 
Cell counting chamber  ASSISTENT 
Cell counter  Ivo 
Centrifuge, small (0,5-2ml-tubes) Biofuge Pico Heraeus 
Centrifuge, large (15/50ml-tubes) Multifuge 3S-R Heraeus 
CO2-Incubator  Heraeus 
Dot-Blot-chamber Minifold Schleicher & Schuell 
Fractionator  Beckman 
Freezer -20°C Premium NoFrost Liebherr 
Freezer -80°C NapCOIL UF 600 Napco 
Gel pouring chamber  Hoefer 
Gel running chamber for SDS-PAGE Mighty small basic unit Amersham Pharmacia 
Grids for electron microscopy 300-mesh Plano GmbH 
Heating block 95°C Ori-Block OB-3 Techne 
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Ice machine AF200 Scotsman 
Laboratory scales 770 Kern 
Li-Cor Scanner  Licor 
Magnetic stirrer Combimag RCO  Ika Labortechnik 
Microscope HC CTR MIC Leica 
Microwave oven KOR-63D7 Daewoo 
Perfusion pump, small P1 GE Healthcare 
Perfusion pump, large Masterflex Cole-Parmer 
pH-Meter 632 Metrohm 
Phosphoimager FX Biorad 
Power supply for electro blotting 
(Western Blot) 
PS-3030D Monacor 
Power supply for Gel electrophoresis  Pharmacia 
Refrigerator 4°C Premium Liebherr 
Rotating shaker RM-2M Neolab 
Shaker for 1,5 ml reaction tubes  Eppendorf 
Table top ultracentrifuge Optima MAX Beckman Coulter 
Teetering shaker DRS-12 Neolab 
Transfer chamber for western blot SD transfer cell Biorad 
Ultracentrifuge Sorvall discovery 90 SE Sorvall, Thermo 
scientific 
Vacuum pump BVC21 Vacuubrand 
Vacuum membrane pump CVC 3000 Vacuubrand 
Vortexer  Cenco 
Water purification system TKA GenPure TKA 
Water bath W6 B. Braun 
 
2.1.3 Chemicals 
Chemical  manufacturer 
Acetic acid  Merck 
Acrylamid/Bisacrylamid (29:1), 30% 
(w/v) 
 Serva Electrophoresis 
Ammoniac  J.T. Baker 
Ammonium peroxide sulphate APS Grüssing 
Ampicillin  Sigma-Aldrich 
Bovine Serum Albumin, Fraction V BSA Carl Roth 
Brilliant Blue R  Chroma-Gesellschaft 
Bromphenol blue  Chroma 
Caesium chloride  Invitrogen/Gibco 
Calcium chloride dihydrate   Merck 
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Cholesterol  Avanti Polar Lipids 
32P-dCTP  Amersham bioscience 
Collagenase  Sigma-Aldrich 
DAPI  Roche Applied Science 
Dimethyl sulfoxide DMSO Merck 
1,2-Dioleoyl-sn-Glycero-3-(Phospjo-L-
Serine) (sodium salt) 
DOPS Avanti polar lipids 
Di-sodium hydrogen phosphate-
dihydrate 
 Grüssing 
Dithiothreitol DTT Fermentas 
D-MEM/F12  Invitrogen 
n-Dodecyl-β-D Maltoside  neoLab 
Easycoll 1,124g/ml Biochrom 
Embedding medium for microscopy Vectashield Vector laboratories 
Ethanol absolute  Sigma-Aldrich 
Ethanol denatured 1% Petroleum 
ether 
 central supply 
Ethylenediaminetetraacetic acid 
(EDTA) 
 Carl Roth 
Ethylene glycol-bis(2-
aminoethylether)-N,N,N´,N´-
tetraacetic acid (EGTA) 
 Sigma-Aldrich 
Fetal Calf Serum FCS various sources 
Formaldehyde solution 37% p.a.   J.T. Baker 
G418 Geneticin Invitrogen 
Gelfiltration standard  BioRad 
Glucose D+  Merck 
Glutamine, L-  Invitrogen 
Glycerine (99,5%)  Sigma-Aldrich 
Glycine  Applichem 
Guanidinium hydrochloride  Applichem 
HEPES  Roth 
Human Serum Albumin, 96-99% HSA Sigma-Aldrich 
Hydrochloric acid 37%  J.T. Baker 
Hydrocortisone hemisuccinate  Sigma-Aldrich 
Hydrogen peroxide (30%)  Merck 
Imidazol  Merck 
Insulin  Sigma-Aldrich 
Isopropyl alcohol  Applichem 
Milk powder, fat-free  Roth 
Magnesium chloride  Merck 
Methanol  J.T. Baker 
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Octyl glucoside  Roth 
Nycodenz  Axis Shield 
Orange G  Sigma-Aldrich 
1-Palmitoyl-2-Oleoyl-sn-Glycero-3-
Phosphocholine 
POPC Avanti Polar Lipids 
1-Palmitoyl-2-Oleoyl-sn-Glycero-3-
Phosphoethanolamine 
POPE Avanti Polar Lipids 
Paraformaldehyde PFA Sigma-Aldrich 
PBS, 10× for cell culture  Invitrogen 
Penicillin/ Streptomycin 5000U/ml / 
5000µg/ml 
Invitrogen 
L--Phosphatidylinositol-4-
Phosphate (Brain, 
Porcine Diammonium salt) 
PIP Avanti Polar Lipids 
Polyethylene glycol 8000 PEG Sigma-Aldrich 
Polysorbate 20 Tween-20 Roth 
Polysorbate 80 Tween-80 Roth 
Potassium chloride  Merck 
Potassium dihydrogen phosphate  Applichem 
Potassium hydrogen phosphate  Merck 
Protease inhibitor-cocktail, EDTA-
free 
PFA Roche applied science 
Rat Serum Albumin RSA Sigma-Aldrich 
Saccharose, D(+)  Carl Roth 
Silver nitrate  Grüssing 
Sodium acetate  J.T. Baker 
Sodium azide  Riedel-de-Haën 
Sodium carbonate  Applichem 
Sodium chloride  Applichem 
Sodium dihydrogen phosphate-
monohydrate 
 Merck 
Sodium dodecylsulfate SDS Serva 
Sodium hydrogen carbonate  J.T. Baker 
Sodium hydroxide  Applichem 
Sodium thiosulfate  Grüssing 
Trichloroacetic acid TCA J.T. Baker 
Tetramethylethylendiamin TEMED Roth 
Tetracycline  Sigma-Aldrich 
Tricine  Sigma-Aldrich 
Urea  Grüssing 
Tris(hydroxymethyl)-aminomethan Tris Roth 
Triton x-100  Sigma-Aldrich 
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Trypan Blue solution, 0,4%  Sigma-Aldrich 
Trypsin (cell culture) 0,05% in PBS PAA 
Uranyl acetate   
Water (ad iniectabilia)  Braun 
Williams Medium E  Invitrogen 
2.1.4 Protein Markers for SDS-PAGE 
 
2.1.5 Antibodies 
2.1.5.1 Primary antibodies 
Antibody Specificity Dilution Source/Manufacturer 
Ma18/7 
(Mouse) 
Monoclonal antibody reacting 
against 20-DPAF-24 in the HBV 
preS1 
1:20 (WB) Heerman et al., 1984 
H 863 (rabbit) Polyclonal antibody reacting 
against HBV preS1/preS2 
1:10.000 (WB) S. Urban 
H363 (rabbit) Polyclonal antibody against 
HBV core 
1:1.000 (IF) H. Schaller 
33633 Human serum, contains anti 
HDV-antibodies 
1:1.000 (IF)  
HYB 069-01 
(mouse) 
Monoclonal antibody against 
human Apolipoprotein A1 
1:1.000 (WB) Dianova 
GTA-7 Human serum, contains anti 
HDV-antibodies 
1:1.000 (IF) Raffaela Romeo, Italy 
DOAE Human serum, contains anti 
HDV-antibodies 
1:1.000 (IF) Raffaela Romeo, Italy 
BTFZ Human serum, contains anti 
HDV-antibodies 
1:1.000 (IF)  
 
2.1.5.2 Secondary antibodies 
Antibody Dilution manufacturer 
Goat anti mouse, Alexa Fluor 488 coupled 1:1.000 (IF) Invitrogen 
Goat anti rabbit, Alexa Fluor 546 coupled 1:1.000 (IF) Invitrogen 
Goat anti Human, Alexa Fluor 555 coupled 1:1.000 (IF) Invitrogen 
Marker size range manufacturer 
Novex sharp Pre-stained protein 
standard 
3,5 – 260 kDa Invitrogen 
PageRuler unstained Protein Ladder 10 - 200 kDa Fermentas 
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Goat anti mouse, Alexa Fluor 680 coupled 1:20.000 (WB) Molecular Probes 
Goat anti rabbit, IR dye 800 coupled 1:20.000 (WB) Invitrogen 
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2.2 Methods 
2.2.1 Cell culture 
All cell culture work was performed under sterile conditions on a laminar flow hood. 
2.2.1.1 HepAD38 cells 
For production of infectious HBV particles, HepAD38 cells were grown in 1- or 2-stacks and 
cultivated for two weeks in HepAD38 culture medium with tetracycline (100ml/ stack) at 
37°C. The subsequent removal of tetracycline (tet off) led to the expression of the HBV 
genome and therefore to the secretion of capsids, Dane-particles and subviral particles. The 
supernatant (SN) from the first two weeks tef off was discarded, since during this time 
period,  the cells produce mainly naked capsids and very little Dane-particles. Starting day 14 
after tet off, SN was collected every four days, centrifuged at 10.000 rpm for 30 min and 
filtered sterile through a 45µm filter. 
 
2.2.1.2 HepaRG  
HepaRG cells were grown at a density of 1,25×106 cells / 12-well plate and cultured for two 
weeks in culture medium at 37°C, 5% CO2. Afterwards, Medium exchange with 
differentiation medium was performed on day 1, 2, 5, 8 and 11. After a two week 
differentiation process, cells in the differentiated islands were susceptible for HBV.  
 
2.2.1.3 Isolation and cultivation of primary hepatocytes 
Here follows the general description of the method; since the employed materials and 
amounts of buffer vary with the species, these are given in a separate Table.  
Mice were sacrificed by cervical dislocation, rats, hamsters and guinea pigs by a CO2-
overdose and rabbits by intravenous injection of Narcoren®. At death, the animal was fixed 
in supine, the abdomen was opened, the liver and surrounding blood vessels were exposed. 
A venous catheter was placed into the Vena cava inferior and the Vena portae was incised. 
The liver was flushed for at least five minutes with 42°C warmed EGTA-solution and 
subsequently perfused with 42° warm collagenase solution, until a swelling of the liver and 
detaching of the liver capsule indicated sufficient digestion. The organ was then removed 
from the abdominal cavity and transferred to the remaining collagenase solution. All further 
steps were performed in a laminar flow under sterile conditions. 
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In a 10cm cell culture dish, the liver capsule was carefully removed using forceps, the 
outflowing hepatocytes filtered through a 100µm cell strainer in order to remove remaining 
connective tissue and singularize cells. After centrifugation (28×g, 5min, 4°C), the cell pellet 
was resuspended in a percoll-solution with a density of 1,063g/ml, separation of vital 
hepatocytes from those undergoing cell death and non-parenchymal cells was achieved by 
centrifugation at 50×g, 10min, 4°C without break. After another washing step (spin at 28×g, 
5min, 4°C), the cells were resuspended in isolation medium and assessed by the trypan blue 
method for viability and cell number.  
For infection experiments, cells were diluted in PHep-I medium and seeded onto collagen 
coated 12 well dishes with a density of 8,8×104 cells /cm2. 4h after plating, the medium was 
changed o PHep-II Medium, 24 h after plating to PHep-infection medium.  
 
EGTA Perfusion buffer 2 mM L-Glutamine, 0.5 % Glucose, 25 mM HEPES, 2 mM EGTA, 
pH7.4 
Collagenase buffer 2 mM L-Glutamine, 0.5 % Glucose, 25 mM HEPES, 3 mM CaCl2, 3 
mg/ ml Collagenase type IV, prepared in Williams E Medium 
 
 Mouse 
Mus 
musculus 
Rat 
Rattus 
rattus 
Hamster 
Mesocricetus 
auratus 
Guinea pig 
Cavia porcellus 
Rabbit 
Oryctolagus 
cuniculus 
Weight Ca. 30g Ca. 150g ca. 80g ca. 200g Ca. 600g 
Catheter 24G 20G 22G 20G 18G 
EGTA-buffer  50ml 150ml 100ml 150ml 250ml 
Collagenase-buffer  50ml 150ml 100ml 150ml 250ml 
Ø Perfusion tubing 1,5mm 7,5mm 7,5mm 7,5mm 7,5mm 
Flow rate 5ml/min 20ml/min 15ml/min 20ml/min 30ml/min 
 
2.2.1.4 Primary Human Hepatocytes (PHH) 
PHH were obtained from Thomas Weiss, University Clinics Regensburg. The cells were 
isolated and cultivated in serum free medium. Liver samples used for this procedure were 
obtained by hepatectomy on patients with metastatic liver tumors or colorectal tumors. All 
procedures were performed according to the guide lines of the Human Tissue and Cell 
Research (HTCR) foundation and with agreement of the patient. 
The PHH were shipped on ice, resuspended upon arrival in cold PHH-I medium and assessed 
by the trypan blue method for viability and cell number. Cells were then seeded in 12-well 
plates at a density of of 4×106 cells /plate. 
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2.2.1.5 PEG-precipitation of virus from HepAd38 supernatant 
18ml of a 40% PEG-solution were added per 100ml cell culture SN. The solution was shaken 
overnight at 4°C and centrifuged (JA-10 Rotor, 60min, 17.600×g, 4°C). The pellet was 
resuspended in 1% of the starting volume and again shaken over night at 4°C. After a short 
centrifugation, the SN was brought to 5% of the starting volume with PBS/10% FCS, 
aliquoted and stored at -80°C.  
 
2.2.1.6 HBV infection of HepaRG and primary hepatocytes 
All infection experiments were performed with an inoculum of 1×104 GE/ cell in HepaRG 
differentiation medium. For inhibition experiments, the cells were incubated for 30 min with 
200nM or 500nM HBV preS/2-48myristoyl before addition of the virus; the peptide was also 
present during virus inoculation. The cells were infected with PEG-precipitated stock virus in 
the presence of 4% PEG for ~16h at 37°C, 5% CO2. The virus was then washed off 
thouroughly with 1×PBS, fresh medium was added. Supernatants of day 7-12 were 
harvested: As marker for infection, secreted HBsAg was measured in a commercial AXSYM-
ELISA.  Cells were fixed with 4% PFA and processed for IF. 
 
2.2.1.7 HDV /WHDV infection of HepaRG and primary hepatocytes 
HDV infections were done with sera from chronically HDV-infected patients obtained from 
xxx, Italy. These sera were not quantified for content of viral RNA; therefore, the exact 
inoculum was unknown. Cells were either infected with 10µl/well GTA-7 serum, 25µl/well 
BTFZ-serum or 15µl/well GTA-4 serum.  
WHDV infections were done with serum from woodchucks; sera were obtained from M. 
Roggendorf, Hannover. These animals, carrying a chronic WHV-infection, were superinfected 
with HDV, resulting in formation of WHV-enveloped HDV particles. 20µl/well were used. 
differentiated HepaRG Cells or freshly isolated primary hepatocytes (day one after isolation) 
were infected with HDV or WHDV sera for 16h at 37°C, 5% CO2. The virus was then washed 
off thouroughly with 1×PBS, fresh medium was added. On day 5 p.i., cells were fixed with 4% 
PFA and processed for IF.  
 
2.2.1.8 Binding assay with radiolabeled preS-peptide on PMH 
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PMH were isolated as described, plated onto collagen-coated 24-well plates and kept in 
serum-free medium. On day 1 after isolation, cells were incubated with 165 nM/well of HBV 
preS/2-48myristoyl-Y125 for 1h at 37°C, 5% CO2 (incubation volume: 300µl/well). Incubation was 
performed in the absence or presence of either 25µM HSA, 1,8µM HDL or both. Following 
incubation, SN were taken off, cells washed three times with 300µl/well 1×PBS and lysed 
with 300µl/well 1N NaOH. Counts per minute (cpm) in all fractions were quantified in a γ-
counter. 
 
2.2.2 Analysis of infections 
2.2.2.1 Immunofluorescence of HBV/ HDV infected cells 
On day five p.i. (HDV) or day 12 p.i. (HBV), cells were fixed for 30 min at 4°C with 4% 
Paraformaldehyde (PFA) and washed with PBS. After permeabilization with PBS/0,25% Triton 
X-100 for 30min at RT, cells were again washed and incubated overnight with a primary 
antibody diluted in PBS/ 5% skimmed milk powder. After another washing step, incubation 
with the secondary antibody, diluted in PBS/ 5% skimmed milk powder was performed for 
1h at RT. The cells were again washed; cells that were not grown on coverslips were then 
stained with 4′,6-Diamidin-2-phenylindol (DAPI, dissolved to 1µg/ml in methanol) and 
washed again; if cells had been plated on cover slips, those were mounted on glass slides 
with Vectashield® mounting medium. Microscopy was performed on a xxx microscope in a 
100× to 400× magnification.  
 
2.2.3 Biochemical methods 
2.2.3.1 Peptide synthesis 
All peptides were synthesized by Alexa Schieck or Thomas Müller (AG Mier, Department for 
nuclear Medicine, University clinics Heidelberg) using solid phase synthesis by the Fmoc/tBu 
method on an Appied Biosystems 433A synthesizer. Fluorescein Isothiocyanat (FITC) was 
coupled onto the ε-amine group of an additional Lysine on position 49. All peptides were 
subsequently purified by preparative High Performance Liquid Chromatography (HPLC) on a 
C18-column, applying a linear gradient from 100% water to 100% Acetonitril in 0,1% 
Trifluoric Acid (TFA). Analysis of the products was done by chromatography on a Merck 
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Chromolith® Performance RP18e-column (100 - 4,6mm; 4ml/min), final purification on a 
Chromolith® SemiPrep RP-18e column (100 - 10 mm; 10 ml/ min). Identity of all peptides 
was confirmed by mass spectrometry.  
 
2.2.3.2 Serum preparation 
Human Blood was taken from healthy donors by medical personnel and collected into serum 
centrifugation tubes. The blood was let to clot for 10min at RT. For rat serum preparation, 
rats were sacrificed by CO2-overdose, fixed in supine and the abdomen was opened. A 
syringe with a 20G-canula was inserted into the vena cava inferior and blood was drawn. 
This was then let to clot o/n. Dog serum and cynomolgus serum was obtained from animals 
used for biodistribution studies of HBV preS-peptides. Blood was taken from animals by 
veterinary personel and let to clot. After clotting, samples were centrifuged for 10 min at 
1000rpm. Supernatant serum was taken off, aliquoted and stored at-20°C. 
 
2.2.3.3 Purification of high density Lipoproteins from human serum 
SEC on Superdex 75 
Serum was isolated as described before. 4ml of sterile filtered serum were applied onto a 
HiLoad 26/60 Superdex 75 column (prep-grade). 1×PBS was used as running buffer, runs 
were performed at 2,5ml/min. Fractions of 5ml were collected and analyzed for HDL-content 
by ApoA1-specific WB.  
Ultracentrifugation 
4ml of each peak fraction from the SEC were pooled (usually fraction A4-A7) and adjusted to 
1,121g/cm3 by addition of 960mg solid sodium bromide. The solution was then subjected to 
ultracentrifugation in a SW60-rotor for 24 h at 345.000×g, 10°C. After centrifugation, the 
solution was ractionated into 8 fractions, 0,5ml each and analyze for HDL-content using an 
ApoA1-specific antibody. 
SEC on Superose 6 
The HDL-containing peak fractions from ultracentrifugation were pooled and concentrated 
too 300µl by centrifugation in a centrifugal filter unit (cut off: 30kDa) for 15 min at 3000×g. 
The concentrate was applied onto a HR 10/300 Superose 6 column. 1×PBS was used as 
running buffer, runs were performed at 0,4ml/min. Fractions of 0,5ml were collected and 
analyzed for HDL-content by ApoA1-specific WB. Peak fractions were again pooled and 
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concentrated; all fractions were analyze for total protein content by coomassie-stained SDS-
PAGE. 
 
2.2.3.4 Size exclusion chromatography (SEC) of peptide-albumin /-serum complexes 
Fluorescein Isothiocyanate (FITC)-labeled peptides were dissolved to a final concentration of 
100µM (Chromatography on a HR 10/300 Superose 6 column) or 200µM (Chromatography 
on Smart-S6 column)  in 1×TN buffer (20mM Tris, 140mM NaCl, pH7,4). Serum albumin was 
dissolved to a final concentration of 40mg/ml (HR 10/300 Superose 6 column) or 13,2mg/ml 
(Smart-S6 column) in 1×TN-Puffer. The peptides were preincubated in given amounts with 
150µM (10/300 Superose 6 column) or 30µM (Smart S6 column) or 75µl human serum for 1h 
at 37°C and applied to the respective column. On the smart S6 column, 50µl were applied, 
runs were performed at 0,04ml/min with 1×TN as running buffer; on the 10/300 superose 6 
column, 300µl were applied, runs were performed at 0,4ml/min. UV-absorption of all elution 
fractions was measured at 280nm (all proteins) and 490 nm (FITC-specific absorption). 
 
2.2.3.5 Fishing of binding partners for HBVpreS/2-48myristoyl in Serum 
HBVpreS/2-48myristoyl -CL was incubated at a final concentration of xxxµM with 1ml of human 
serum from a healthy, vaccinated donor in a final volume of 10ml for 1h at 4°C in the dark. 
The solution was then exposed to UV-light for 10min on ice, filled up to 30ml with HisTrap 
binding buffer and applied onto a 1ml Nickel agarose column at 0,5ml/min. Unspecifically 
bound proteins were washed off with 5column volumes (CV) of wash buffer (0,5ml/min), 
elution of bound molecules was performed with a linear gradient from 20mM to 500mM 
imidazole over 10CV (0,5ml/min). UV absorption of all elution fractions was measured at 
280nm.  
 
2.2.3.6 Fishing of binding partners for HBVpreS/2-48myristoyl on primary hepatocytes 
Primary Rat Hepatocytes (PRH) were isolated by the method described in xxx and 
resuspended in 1×PBS. 2×108 cells were then incubated in a volume of 30ml with a final 
concentration of 1µM HBVpreS/2-48myristoyl CL-peptide at 4°C for 1h in the dark. Following 
exposure of the suspension to UV-light for 10min on ice, cells were pelleted (28×g, 5min, 
4°C), washed twice with 0,5%BSA/PBS, twice with PBS and lysed with HisTrap binding buffer, 
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6M Urea (rotation for 1h, 4°C; addition of 1protease-inhibitor cocktail (Roche) pellet, EDTA-
free). For complete lysis, the solution was treated with ultrasound (3min, 50%). Aggregates 
were removed by a short ultracentrifugation (53.000×g, 20min, 4°C), the supernatant sterile 
filtered and applied onto a 1ml nickel sepharose column at 0,5ml/min. Unspecifically bound 
proteins were washed off with 5column volumes (CV) of wash buffer (0,5ml/min), elution of 
bound molecules was performed with a linear gradient from 20mM to 500mM imidazole 
over 10CV (0,5ml/min). UV absorption of all elution fractions was measured at 280nm.  
 
HisTrap binding buffer 20mM Sodium Phosphate, NaCl, 6M Urea, 20mM Imidazole, pH8,3 
HisTrap wash buffer 20mM Sodium Phosphate, NaCl, 6M Urea, 20mM Imidazole, pH6,3 
HisTrap elution buffer 20mM Sodium Phosphate, NaCl, 6M Urea, 500mM Imidazole, pH6,3 
 
2.2.3.7 Mass spectrometry 
Mass spectrometry (matrix-assisted laser desorption/ ionisation / time of flight, MALDI-TOF) 
was performed by the group of Dr. Thomas Ruppert on a Ultraflex TOF/TOF (Bruker). 
 
2.2.4 Assay for membrane activity analysis 
2.2.4.1 Liposome production 
For leakage assays, liposomes were prepared with a 15mM lipid mastermix solution 
containing either 85mol% POPC and 15mol%DOPC (inert lipid mixture) or 35 mol% POPC, 
25 mol% DOPS, 25 mol% POPE, 5 mol% PI and 10 mol% Cholesterol (physiological mixture). 
The lipids were dissolved in Chloroform ad transferred to glass tubes; 100µl of mastermix 
were used for each final gradient. The chloroform was left to evaporate for 15 min under a 
nitrogen gas flow; the lipids were then dried thoroughly by applying vacuum for 1h at RT 
(high vaccum applied by membrane pump, 3bar). Per final gradient, 500µl Buffer A (100mM 
KCl, 25mM HEPES, 10% glycerol, pH7,4) containing 1% octyl glucoside (OG)were then added 
to solve the dried lipids and shaken for 1h at RT. For reconstitution of the liposomes, a 
double volume of buffer A ( containing 12,5mM HPTS, 45mM DPX if desired) without OG was 
then added drop by drop while vortexing the solution. Thereby, the OG concentration fell 
below the critical micellar concentration(CMC), leading to the formation of liposomes. 
Removal of the detergent and surplus dye was reached by dialysis of the solution against 5l 
of buffer A overnight at 4°C. The liposomes were then concentrated by a Nycodenz gradient. 
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Therefore, the dialyzed solution was mixed with an equal volume of 80% Nycodenz in buffer 
A, layered with 1/4 volume of 30% Nycodenz in buffer A and 200µl of buffer A. 
Centrifugation at 55krpm for 3h40, 4°C led to the flotation of liposomes and their efficient 
separation from remaining free dye.  
The floated liposomes were taken off, aliquoted and stored until further usage at -80°C. 
 
2.2.4.2 membrane activity assay of HBV preS derived lipopeptides on liposomes 
in a 96well plate, 1µl of HPTS/DPX containing liposomes (corresponds to 80µM in final 
volume) and 3,5 or 7µl (corresponding to 75-150µM in final volume) preS-peptides were 
incubated at 37°C in a final volume of 70µl. The preS peptides were dissolved in 50% DMSO 
/buffer A; if 3,5µl peptide were used, 3,5µl 50%DMSO/buffer A were added to the reaction. 
During this time, absorption and emission of the HPTS-dye was measured at 460nm and 
520nm, respectively, in a Fluoroscan Ascent FL fluorescence plate reader. At the end of the 
incubation time, 10µl of a 2,5% (w/v) octyl maltoside solution were added; this led to 
complete lysis of all liposomes and total dequenching of the HPTS dye. The fluorescence 
signal obtained by the lysis was set as 100%; values obtained during the incubation were 
expressed as percentage of total lysis employing the following formula: 
Fluorescence (%) = (( Ft - Fmin )/( Fmax - Fmin )) * 100 
Ft: measured fluorescence at time point t 
Fmin: minimal measured fluorescence (corresponding to no membrane activity) 
Fmax maximal measured fluorescence (corresponding to total lysis by octyl maltoside).  
 
2.2.4.3 flotation assay with HBV preS-derived lipopeptides on liposomes 
50µM preS-peptides dissolved in 50% DMSO/buffer A were preincubated with 640µM lipid 
in a final volume of 150µl for 30min at 37°C. an equal volume of 80% Nycodenz was added, 
layered with 700µl of 30% Nycodenz and ~100µl of buffer A in quick seal tubes. Flotation 
was performed by centrifugation in a TLA120 Rotor for 45min at 4°C, 386 000×g. The 
gradient was then fractionated from the bottom into 8 fractions, ~100µl per fraction; 15µl of 
each fraction and 1,5µl input were analyzed by western blot with a preS1-specific antibody.  
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2.2.4.4 Electron microscopy of liposomes and peptides 
peptides were dissolved to 1mM in buffer A (100mM KCl, 25mM HEPES, 10% glycerol, 
pH7,4). Liposomes containing no dye were used. Increasing amounts of peptide solution 
were added to 1µl liposome solution, buffer A was added to a final concentration of 15µl; 
this solution was incubated for 1h at 37°C.  
10µl of this preincubated mixture were then pipetted onto a parafilm layer, a pioloform-
coated electron microscopy grid (300 mesh, no carbon coating, no glow discharge) was laid 
on the drop for 10 min so that liposomes could adsorb. surplus solution was removed by 
short contact with filter paper. Negative staining was performed in two steps; first, a short 
(5sec) incubation with a first drop of 1% uranyl acetate (UA), second, a longer incubation 
with a second drop UA (30sec). The grids were then carefully dried on filter paper and stored 
at RT until microscopy was performed.  
 
2.2.5 Analysis methods 
2.2.5.1 SDS-PAGE 
Samples to be analyzed were dissolved in 2×SDS sample buffer (200mM Tris/HCl pH6,8, 
6%SDS, 20% Glycerol, 10%DTT, 0,1mg/ml bromphenol blue, 0,1mg/ml Orange G) and heated 
for at least 10min at 95°C. Separation was performed on acrylamid-gels after the method of 
Lämmli (XXX) or Schägger (XXX).  
 
Composition of gels for electrophoresis by the method of Lämmli 
 Stacking gel Separating gel 
H2Odd
 (ml) 11 17,5 
4×Stacking gel buffer (ml) 5 - 
4× Separating gel buffer (ml) - 12,5 
BAA (ml) 4 20 
Temed (µl) 10 25 
APS Spatula tip Spatula tip 
Final volume (ml) 20 50 
 
Composition of buffers for electrophoresis by the method of Lämmli 
4×Stacking gel buffer 4×Separation gel buffer 1× SDS running buffer 
0,5 M Tris/Cl pH 8,8 
0,4 % SDS 
0,01 % NaN3 
1,5 M Tris/Cl pH 8,8 
0,4 % SDS 
0,01 % NaN3 
0,025 M Tris 
0,086M glycine 
0,0035M SDS 
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Composition of gels for electrophoresis by the method of Schägger 
 Stacking gel 12% sep. gel 16% sep. gel 20% sep. gel 
H2Odd (ml) 10,6 10,9 5,6 0,3 
3×Schägger gel 
buffer(ml) 
6,7 13,3 13,3 13,3 
BAA (ml) 2,7 15,8 21,1 26,4 
Temed (µl) 20 40 40 40 
APS Spatula tip Spatula tip Spatula tip Spatula tip 
Final volume (ml) 20 40 40 40 
 
Composition of buffers for electrophoresis by the method of Schägger 
3× Schägger gel buffer Cathode buffer Anode buffer 
3 M Tris pH 8,45 
0,3 % SDS 
 
0,1 M Tris 
0,1 M Tricin 
 0,1 % SDS 
0,2 M Tris pH 8,9 
 
2.2.5.2 Transfer of proteins separated by SDS-PAGE onto a nitrocellulose membrane 
(Western blot) and immunodetection 
The electric transfer of proteins onto a nitrocellulose membrane was done using the semi-
dry method. On top of two filter papers soaked in Schäffer-Nielsen transfer buffer was laid 
the presoaked membrane. The protein gel was also soaked in buffer and laid onto the 
membrane, followed by another two layers of soaked filter paper. Applying a voltage of 15V 
for 30min transferred proteins from the gel onto the membrane.  
free binding sites on the membrane were blocked by incubation with TBST-M (1×TBS, 0,05% 
Tween-20, 5% skimmed milk powder) for at least 1h at RT. The membrane was washed three 
times for 5min with TBS-T (1×TBS, 0,05% Tween-20) and incubated with the first antibody 
diluted in TBST-M) (2h at RT or overnight at 4°C). The membrane was again washed (three 
times, 5min, TBS-T) and incubated for 1h with the secondary antibody (diluted in TBS-T for 
detection with ECl, diluted in TBS for detection with Licor). for fluorescence-based detection, 
the blot was then washed four times with TBS and scanned on a Licor®-reader. In case of a 
peroxidase-coupled secondary antibody, the membrane was washed four times with TBS-T, 
swung in ECL-reagent (5ml of ECL-I and 5ml of ECL-II) for 2min and exposed to a 
photosensitive film, which was then developed in a developing machine. 
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Solutions for western blot 
Schäffer-
Nielsen-
Transfer buffer 
1×TBS 1×TBS-T ECL-I ECL-II 
0,05M Tris 
0,02M Glycine 
 0,04% SDS 
10% Methanol 
pH 9-9,4 
0,14M NaCl 
0,02M Tris 
pH8 
1×TBS with 
0,05% Tween-
20 
100mM Tris-Cl pH 
9,35 
   4,5mM Amino-
phthalhydrazid 
8,5 mM coumaric 
acid 
100mM Tris-Cl 
pH 9,35 
0,004% H2O2 
2.2.5.3 Silver staining of SDS-PAGE gels 
For visualization of proteins after electrophoresis, gels were stained with silver nitrate. First, 
the gel was fixed over night or for 1h in Fix-1, then for 30 min in Fix 2 and two times 15min in 
Fix 3. Following impregnation with Solution A, the gel was washed 3 times with H2Odd (1min 
each) and stained with solution B for12min in the dark. After two more washing steps with 
H2Odd , developing solution was added, left on the gel until a sufficient stain was reached and 
discarded. The reaction was stopped by addition of a 3% acetic acid solution for 1min, the 
gel was then kept in H2Odd.  
 
Solutions for silver stain 
Fix 1 Fix 2 Fix 3 Solution A Solution B Solution C 
50% 
methanol, 
12% acetic 
acid 
10% 
ethanol, 5% 
acetic acid 
10% ethanol 0,02% 
Sodium 
thiosulfate, 
0,02% 
formaldehyde 
in H2Odd 
0,02% Sodium 
thiosulfate, 
0,02% 
formaldehyde, 
0,2% silver 
nitrate in 
H2Odd 
0,0003% 
Sodium 
thiosulfate, 
0,02% 
formaldehyde, 
3% sodium 
carbonate in 
H2Odd 
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3. Results 
In this work, several sets of peptides derived from the HBV preS1-domain have been used. A 
schematic representation of the respective peptides is given in fig. 3.1. All peptides are 
modifications of the preS/2-48myristoyl-peptide (fig. 3.1.A) corresponding to the preS1 N-
terminus of HBV genotype D. 
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Fig. 3.1: Schematic representation of peptides used in this work. The zigzag line represents the N-terminal 
acylation, numbers indicate amino acid positions, the essential site is depicted in light gray.  
A: The myristoylated wildtype. 
B: Crosslinker (CL)-peptides. The star indicates an aryl azide-moiety, the C-terminal His-tag is indicated (His6).  
C, D: Fluorescein- isothiocyanate (FITC)-labeled preS-peptides, either carrying mutations or different N-terminal 
acylations.  
E: Radioisotope labeled preS-peptide. Position of the 
125
I-labeled D-tyrosine on the C-terminus is indicated.  
F-I: Different stearoylated full-length, stearoylated N-terminally shortened or otherwise acylated full length 
peptides used for membrane activity assays. Unless indicated otherwise, all peptides correspond to the 
sequence from HBV genotype D.  
 
3.1 Binding of HBV preS1 derived lipopeptides to serum factors  
HBV preS-derived lipopeptides comprising the amino acids 2-48 and a N-terminal 
myristoylation (HBV preS/2-48myristoyl) show a strong liver tropism and marked serum stability 
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when injected into mice. While mutations in the essential site (amino acids 9-15) abort the 
liver specificity and leads to equal distribution of the peptide throughout all organs, removal 
of the fatty acid results in rapid renal excretion 63. These findings support the hypothesis that 
one or several serum factors binding and stabilizing the peptide must exist. 
In order to assess this putative interaction, a size exclusion chromatography (SEC) assay was 
employed using fluorescein-isothiocyanate (FITC)-labeled preS-peptides. The FITC-molecule 
was introduced during solid-phase synthesis, assuring a equimolar ratio of label : peptide. 
These peptides have been shown to be efficient in inhibiting HBV infection 64. Peptides were 
preincubated in absence or presence of serum or serum components and subjected to size 
exclusion chromatography (SEC) on a superose-6 column. During chromatography, proteins 
were separated according to their size; large proteins eluted earlier, small proteins later. 
Every protein eluted at a specific ratio of elution volume (Ve) to void volume (V0) (Ve/V0-
ratio), the largest proteins eluting with the void volume at a Ve/V0-ratio of 1,00. 
Measurement of the UV-absorption of all elution fractions at 280nm and 490nm allowed 
detection of all proteins or only the FITC-peptide, respectively. A shift in the FITC-specific 
elution signal would then indicate binding to another protein.  
3.1.1. Identification of preS-binding partners 
3.1.1.1 HBV preS/2-48myristoyl showed a size shift in SEC when preincubated with serum 
For a first assessment of binding, an acylated wildtype (wt) and a non-acylated wt peptide 
were used (fig. 3.1 C). Serum subjected to SEC eluted in a characteristic pattern, showing 
several peaks, the largest eluting at an Ve/V0-ratio of 1,96 (fig. 3.2 A). When preincubated 
with buffer, the preS-peptide eluted at a Ve/V0-ratio of 2,38 (fig. 3.2 B).  
Preincubation of the HBV preS/2-48myristoyl -FITC peptide with serum led to a marked shift in 
the FITC-specific elution signal, now overlapping with the serum-peak at Ve/V0 =1,96 (fig. 3.2 
C). This shift, however, was not observed when the non-acylated preS/1-48 FITC peptide was 
preincubated with serum (fig. 3.2 C).  
These results clearly indicated an acylation-dependent binding of the preS-peptide to a 
serum component. Since the non-acylated variant showed no shift in elution, a possible 
artefact caused by the FITC-molecule could be ruled out.  
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Fig. 3.2: Acylation dependent binding of HBV preS-peptides to serum components. A: 75µl human serum 
preincubated with TN-buffer (1h, 37°C). Blue curve: UV280. Red curve: UV490. B: 50µM HBV preS/1-48 
preincubated with TN-buffer. Blue curve: UV280. Red curve: UV490 .C: 50µM preS/1-48 (dashed red curve) or 
preS/2-48
myristoyl
 (continuous red curve) preincubated with 75µl serum (corresponds to 160µM albumin). Blue 
Curve: UV280. Elution profiles from SEC on a HR30/100 Superose 6 column are shown; UV-absorption at 280nm 
(left y-axis) or 490nm (right y-axis) is given, the elution volumes are normalized for the void volume of the 
column (V0, =8ml). Running conditions for all runs: 4°C, 0,4ml/min, running buffer: TN-buffer (20mM Tris, 
140mM NaCl, pH7, 4). Representative data of 3 independent experiments are shown. 
 
3.1.1.2 Functional peptides carrying a crosslinker moiety for identification of binding 
partners 
In order to identify the interaction partners of preS-peptides, a biochemical crosslinking 
assay was used. For this purpose, a photoreactive aryl azide-moiety was coupled to a lysine 
introduced on position 19 of a set of preS-peptides (fig. 3.1 B). Upon exposure to UV-light, 
this molecule forms reactive nitrenes that rapidly establish covalent bonds to molecules in 
close proximity. A hexa-histidine tag (his-tag) was introduced on the C-terminus of those 
peptides for purification of formed complexes via affinity chromatography on nickel-
sepharose columns.  
The modified peptides are not altered in their ability to inhibit HBV-infection 
To assure that the alterations introduced into these peptides do not influence their ability to 
inhibit HBV infection, they were added in increasing concentrations to a HBV-infection assay 
on HepaRG cells. As control, unaltered myristoylated wildtype peptide was used. 
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While the uncompeted infection led to a HBsAg-secretion of ~30 signal over cutoff (S/CO) 
(fig. 3.3, black bar), addition of 500nM myristoylated wildtype (wt) peptide reduced 
secretion about six fold (fig. 3.3, dark grey bar). A similar reduction was observed already at 
100nM of the peptide carrying the aryl azide moiety and His-tag (preS/2-48myristoyl-CL). 
Addition of higher amounts of this peptide did not reduce infection further (fig. 3.3, light 
grey bars).  
In contrast, a crosslinker-peptide where 5 aa in the essential site were replaced by alanine 
(preS/2-48 Ala11-15myristoyl-CL) did not influence HBV infection, independently of the amount 
added (fig. 3.3, white bars). Thus, the alterations made on the preS-peptide for 
identification of binding partners do not influence its functionality.  
 
 
Fig. 3.3: preS/2-48
myristoyl
 -CL inhibits HBV-infection in a sequence-dependent manner. HepaRG cells were 
infected with a multiplicity of infection 
24
 of 1×10
4 
in the absence of inhibitor or presence of 500nM unaltered 
WT preS-peptide, 100-2000nM preS/2-48
myristoyl
-CL or 100-2000nM preS/2-48 Ala11-15
myristoyl
-CL. Supernatant 
60
 
from day 7-12 was harvested, secreted HBsAg measured by ELISA. Representative data of 3 independent 
experiments are shown. 
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3.1.1.3 Human Serum Albumin and Apolipoprotein A1 bind to preS-peptides 
In order to identify binding partners, human serum was incubated with preS/2-48myristoyl-CL, 
preS/2-48 Ala11-15myristoyl-CL or preS/1-48-CL (fig. 3.1 B); formed complexes were purified by 
affinity chromatography on nickel-sepharose.  
Analysis of the elution fractions by preS1-specific western blot (wb) and silver stain SDS-
PAGE showed two bands in the elution fractions of the crosslinker assay with acylated wt 
and mutant peptide (fig. 3.4, left and middle panel). The upper band ran at an apparent 
molecular weight of 70-75 kDa, the lower band at an apparent molecular weight of 30-35 
kDa. Assuming that these bands correspond to peptide-serum factor-complexes, subtraction 
of the peptides´ molecular weight (6,5 kDa) results in binding partners with a molecular 
weight of 63-68 kDa and 23-28 kDa, respectively. 
Neither band showed up in the elution fractions when the non-acylated peptide was used, 
indicating acylation-dependent, sequence-independent binding (fig. 3.4, right panel).  
 
 
Fig. 3.4: Myristoyl-dependent, sequence-independent binding of preS-peptides to two serum components. 
150µM of preS/2-48
myristoyl
-CL (left panel), preS/2-48 Ala11-15
myristoyl
-CL (middle panel) or preS/1-48-CL right 
panel) were incubated with 1ml of human serum for 1h at 37°C, filled ad 10ml with lysis buffer and applied to a 
nickel-sepharose column in presence of 20mM Imidazole. After washing with 50mM Imidazole, bound 
molecules were eluted with a 500mM Imidazole step gradient over 10 column volumes. Wash and elution 
fractions were separated by SDS-PAGE and analyzed by wb using a HBV preS1-specific antibody (Ma18-7) 
(upper panels) or by silver stained SDS PAGE (lower panels). Representative data of 2 independent 
experiments are shown. 
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Peak fractions of the affinity chromatographies with myristoylated wildtype peptide were 
analyzed by mass spectrometry (data not shown); proteins corresponding to the preS1-
specific bands in WB were identified to be human serum albumin (HSA, upper band) and 
apolipoprotein A1 (ApoA1, lower band).  
With 66 kDa (serum albumin) and 24 kDa (apolipoprotein A1), these proteins correspond to 
the expected sizes. Both proteins are involved in the systemic transport of hydrophobic 
substances, which makes them likely interaction partners for an acylated peptide. 
Next, the characterization of both interactions, their possible role in the liver tropism and 
hepatocyte binding of preS-peptides as well as their influence on HBV infection came into 
focus. In the following, analysis of the albumin-peptide interaction will be presented, 
followed by data concerning the ApoA1-peptide binding. The influence on hepatocyte 
binding and HBV-infection has always been assessed in parallel assays; therefore, these data 
will be presented together in later chapters. 
3.1.2 The peptide - HSA interaction 
3.1.2.1 HBV preS peptides bound HSA in the SEC-assay 
In order to validate HSA as binding partner for preS-peptides, the SEC-assay was performed 
with purified HSA. Therefore, HSA was incubated either with buffer or with acylated wt, 
acylated mutant or non-acylated wt peptide (fig. 3.1 C) and subjected to SEC.  
HSA eluted as sharp peak at a Ve/V0-ratio of 2,03 (fig. 3.5, black curve). Preincubation with 
acylated wt peptide led to the described shift in the 490nm UV-absorption (see chapter 
3.1.1.1), indicating binding of the peptide to HSA (fig. 3.5, green curve). When a peptide 
carrying a mutation in the essential site (D-amino acids 11-13) was preincubated with HSA, 
the size shift was also observed (fig. 3.5, red curve). The independence of the interaction 
from the peptide´s sequence was confirmed by these findings. The non-acylated wt peptide 
showed no size shift in this assay (fig. 3.5, blue curve), giving additional affirmation of the 
acylation dependence.  
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Fig. 3.5: HBV preS-peptides bind HSA in an acylation dependent, sequence-independent manner. 150µM HSA 
were incubated with TN-buffer (black line) or 50µM HBV preS/2-48 
myristoyl 
(green curve)
 
, 50µM HBV preS/2-48 
(D-AS11-13)
myristoyl
 (red curve) or 50µM of HBV preS/1-48 (blue curve) for 1h at 37°C and subjected to SEC on a 
superose 6 column. Elution profiles from SEC on a HR30/100 Superose 6 column are shown; UV-absorption at 
280nm (left y-axis) or 490nm (right y-axis) is given, the elution volumes are normalized for the void volume of 
the column (V0, =8ml).running conditions for all runs: 4°C, 0,4ml/min, running buffer: TN-buffer. Representative 
data of 2 independent experiments are shown. 
 
3.1.2.2 The peptide-HSA binding depends on the length of the N-terminal acylation 
Since the observed interaction was found to depend only on the N-terminal acylation, the 
influence of the length of the N-terminal fatty acid was assessed. Peptides with wt sequence, 
carrying C5-, C8-, C12-, C14- or C18 fatty acids or a cholesterol moiety N-terminally (fig. 3.1 
D) were preincubated with HSA and subjected to SEC.  
Non-acylated peptides did not bind albumin (fig. 3.6, dark blue curve). Peptides carrying 
acylations shorter than C12 showed no binding to HSA; a short fatty acid was not enough to 
confer a sufficient hydrophobicity for binding, the hydrophilic peptide part dominated (fig. 
3.6, green and red curve). With a C12-acylation, the on-rate approximately equaled the off-
rate, leading to a ~50% binding (fig. 3.6, pink curve), while C14- and C18-acylations led to 
complete binding of the peptides, being hydrophobic enough for a strong interaction with 
the fatty acid transporter HSA (fig. 3.6, grey and orange curve). A peptide carrying a 
cholesteryl moiety on its N-terminus also bound HSA (fig. 3.6, purple curve). 
The peptide´s affinity to albumin thus increased with the length of the N-terminal fatty acid, 
therefore, with its hydrophobicity.  
 
Results 
 
 
56 
 
Fig. 3.6: Binding of HBV preS-peptides to HSA depends on the length of the N-terminal acylation.  
150µM HSA were incubated with buffer (black curve) or 50µM of a non-acylated (blue curve), C5-acylated 
(green curve), C8-acylated (red curve), C12-acylated (light blue curve), C14-acylated (grey curve), C18-acylated 
(orange curve) or cholesteroylated (purple curve) preS-peptide for 1h at 37°C and subjected to SEC on a 
superose 6 column. Elution profiles from SEC on a HR30/100 superose 6 column are shown; UV-absorption at 
280nm (left y-axis) or 490nm (right y-axis) is given, the elution volumes are normalized for the void volume of 
the column (V0 =8ml). Running conditions for all runs: 4°C, 0,4ml/min, running buffer: TN-buffer. 
Representative data of 2 independent experiments are shown. 
 
In order to confirm that the observed shift in the FITC-signal corresponds to the preS-peptide 
and is not caused by free FITC, three peak fractions from an SEC-run with C14-, C18- and a 
cholesteroylated peptide preincubated with HSA were analyzed by silver stained SDS-PAGE 
and HBV preS1-specific wb. For all three peptides, a preS1-specific signal could be detected 
in the HSA-peak fractions, running below 15 kDa (fig. 3.7 A) At this molecular weight, a 
diffuse band could also be observed in the silver stain gel (fig. 3.7 B). The HSA-band was 
visible at ~60-70 kDa in the silver stained SDS-PAGE (fig. 3.7 B) and also, not distinguishable 
as clear band, but as background on the wb slightly above 60 kDa (fig. 3.7 A). Above the 
HSA-background, a preS1-specific band was again visible; this band possibly corresponds to 
albumin-bound peptide. A small fraction of the complex would then have withstood the 
denaturing and reducing conditions of SDS-PAGE. Taken together, these data confirm that 
preS-peptides bind to HSA.  
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Fig. 3.7: Confirmation of the peptide binding to HSA by western blot and silver stained SDS-PAGE.  
Peak fractions from SEC-runs of preincubated HSA with either preS/2-48
myristoyl
, preS/2-48
stearoyl 
or preS/2-
48
cholesteroyl
 were separated by SDS-PAGE on a 14% Schägger-gel.  
A: Western blot using a HBV preS1-specific antibody (Ma18-7).  
B: Silver stained SDS-PAGE. Sizes of molecular weight markers are indicated.  
 
3.1.2.3 The peptide-HSA binding in vivo  
Having identified and characterized the peptide-HSA interaction in vitro, confirmation of the 
observed effect in vivo was sought. In the course of a preclinical study for Myrcludex B, an 
HBV preS-derived lipopeptide developed for therapeutic treatment of HBV infection, beagle 
dogs received intravenous injections of 123I-labeled HBV preS/2-48 myristoyl (fig. 3.1 E). 10min 
and 1h after injection, blood samples were taken and serum was prepared. Aliquots of these 
sera were then subjected to SEC, UV-absorption and radioactivity of elution fractions were 
measured. Peak fractions were analyzed by coomassie-stained SDS-PAGE. As the values from 
both times points did not differ, data from the 1h-time point only are shown (fig. 3.8).  
In the SEC, the radioactivity peak (fig. 3.8, dashed line) overlapped with the UV-peak 
corresponding to serum albumin (3.8, black line). The radioactivity measured was in the 
same order of magnitude after 10 min and 1h (~1×105 counts per minute), showing that the 
labeled peptide bound rapidly after injection to albumin and remained bound. The 
coomassie-stained SDS-PAGE of the peak fractions showed a strong band at ~66 kDa (inlaid 
panel), confirming that this peak indeed corresponds to serum albumin.  
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Fig. 3.8: HBV preS-peptides bound to serum albumin in vivo. 86MBq/14µg of HBV preS/2-48myr Tyr49-
123
I 
peptide were injected subcutaneously into the left hind leg of female beagle dogs that had been anaesthetized 
with ketamin (10mg/kg) and xylazine (2mg/kg). 1h after Injection, blood was taken, serum was prepared and 
300µl were subjected to SEC. Elution profile from SEC on a HR30/100 Superose 6 column is shown; Left y-axis: 
UV-absorption at 280nm. Right y-axis: measured radioactivity. Elution volumes are normalized for the void 
volume of the column (V0, =8ml). Running condition: 4°C, 0,4ml/min, running buffer: TN-buffer.  
 
3.1.2.4 The dissociation constant (KD) for the peptide-HSA binding was found to be in the 
micromolar range 
In order to determine the strength of the peptide-HSA interaction, increasing amounts of 
FITC-labeled preS-peptides were incubated with a fixed amount of HSA (30µM final 
concentration) and subjected to SEC. The amount of peptide was varied over a broad range 
(1µM-90µM final concentration). In this range, saturation of the albumin and therefore the 
appearance of a second peptide UV490-peak, corresponding to unbound peptide, was 
expected. Integration of the elution profile peaks at UV=490nm corresponding to bound 
peptide and unbound peptide was then performed using the Unicorn-software (GE 
Healthcare). Exemplary runs for three selected peptide concentrations are shown in fig. 3.9 
A. When preincubation was performed with the C12-acylated peptide (fig. 3.9 A, upper 
row), a peak corresponding to unbound peptide was detectable already at 5µM peptide. 
While the bound peptide-peak increased when more peptide was added, the unbound-
peptide peak rose at a higher rate. The C14-acylated peptide (fig. 3.9 A, middle row) was 
entirely bound to albumin up to an equimolar ratio; higher peptide concentrations led to 
appearance of an unbound peptide-peak. The C18-acylation conferred binding to albumin 
even at a molar excess of peptide (fig. 3.9 A, lower row). 
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For calculations, the peak corresponding to bound peptide was integrated between Ve/V0 = 
1,4 - 2,4; The concentration of unbound peptide was calculated by integrating between 
Ve/V0 = 2,4 and 3,4.  
The dissociation constant KD of an interaction is defined by the concentration at which 50% 
of the ligands binding sites are occupied (θ = 0,5 with θ= fraction of occupied ligand binding 
sites). This value θ can be calculated by the formula   
    
          
 with [RL] corresponding to 
the concentration of the receptor-ligand complex and [R] to the concentration of the 
unbound receptor. In this case, the receptor was HSA and the ligand the peptide. The 
concentration of the HSA-peptide complex [HSA-peptide] was calculated for each peptide 
concentration by the formula                                        
               
                . This 
allowed the calculation of θ by   
         
            
 . The obtained values were then plotted 
against the input peptide concentration. A linear fit curve was drawn using the Graphpad 
software which also allowed calculation of the KD and the maximal bound peptide per HSA, 
Bmax (fig. 3.9 B).  
This assay was performed with the C12-, the C14- and the C18-acylated preS-peptide (fig. 3.1 
D). 
In this way, the dissociation constant for preS/2-48 lau (C12)-HSA-interaction was determined 
to be of 63,25 µM (fig. 3.9 B, green curve); for the preS/2-48 myr 120-HSA of 17,78 µM (fig. 3.9 
B, red curve). PreS/2-48stea (C18) was found to bind to HSA with a maximal amount of 10 
peptide molecules per HSA (fig. 3.9 B, blue curve), leading to a KD-value of 289,7 µM.  
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B 
A 
Fig. 3.9: Binding curves for the peptide-HSA interaction. A: Increasing amounts of either C12-, C14- or C18- 
acylated HBV preS-peptide were incubated with 30µM HSA and subjected to SEC on a Smart-Superose 6 
column; exemplary runs with 5µM, 30µM and 60µM of each peptide are shown. Left y-axis: UV-absorption at 
280nm. Right y-axis: UV-absorption at 490nm. 
B: Ratios of bound peptide /total albumin were calculated and plotted against the amount of input peptide. 
Linear regression curves were calculated according to the "one site - specific binding" model (GraphPad 
software). calculated values of the respective maximal binding (Bmax) and the dissociation constant (KD) are 
indicated. Binding studies have been performed twice with the myristoylated peptide and once with the 
stearoylated and the laurinoylated peptide. 
 
A 
B 
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3.1.3 PreS-peptides bound to Serum components from other species 
In the course of preclinical studies for Myrcludex B as therapeutic agent against HBV 
infection, biodistribution studies have been performed in different species such as rats, 
cynomolgus monkeys and beagle dogs. Albumin binding of preS peptides to albumin or 
serum from these species was assessed.  
Binding could be detected when using serum albumin from rats (fig. 3.10 A), rat serum (fig. 
3.10 B), beagle dog serum (fig. 3.10 C) or cynomolgus monkey serum (fig. 3.10 D). While the 
preS-peptide bound to primary hepatocytes from rat and beagle dog, it did not bind to 
hepatocytes from cynomolgus monkeys 64, nor could liver tropism be detected in these 
animals (A. Schieck, personal communication). The N-terminal acylation therefore confers 
binding to albumin in a wide range of species; the differences in liver tropism indicate that 
the albumin-interaction plays no role in the transport of the peptide to the liver. 
 
Fig. 3.10: HBV preS-peptides bind to albumin from other species. 150µM RSA (A) or 75µl serum from rat (B), 
beagle dog (C) or cynomolgus monkey (D) were incubated with 50µM of HBVpreS/2-48
myristoyl
 (HBVpreS/2-
48
stearoyl
 for the cynomolgus serum) for 1h at 37°C and subjected to SEC. Elution profiles from SEC on a 
HR30/100 Superose 6 column are shown; UV-absorption at 280nm (left y-axis) or 490nm (right y-axis) is given, 
the elution volumes are normalized for the void volume of the column (V0, =8ml). Running conditions for all 
runs: 4°C, 0,4ml/min, running buffer: TN-buffer. Representative data of 2 independent experiments are shown.  
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3.1.4 Binding of HBV preS-peptides to high density lipoproteins 
Apolipoprotein A1, the main protein constituent of high density lipoproteins (HDLs), was 
identified as binding partner for preS derived lipopeptides. This interaction was therefore 
analyzed in vitro by the SEC-assay. 
3.1.4.1 HDLs were purified from human serum 
For assessment of HDL-peptide binding, HDLs were purified from human serum by a three-
step purification method. This consisted of a preparative gel filtration on a superdex 75 
column, flotation by ultracentrifugation followed by SEC on a Superose 6 column.  
 
Separation of human serum on a superdex 75 column 
When serum was subjected to SEC on a superdex 75 column, serum components eluted in 
two main peaks (fig. 3.11). The first peak eluted between Ve/V0 of 1,0 and 1,2, the second 
between Ve/V0 of 1,3 and 1,5. Analysis of the elution fractions by ApoA1-specific wb showed 
a positive signal in very early elution fractions (Ve/V0-ratio of 1,2) (fig. 3.11). This elution 
volume was close to the void volume of the column and corresponded to a molecular weight 
of 380 kDa (calculated using the UNICORN-software, based on standard run on the same 
column). Monomeric uncomplexed ApoA1 has a molecular weight of 24 kDa, and would thus 
be expected to elute at later fractions. This indicates that this positive signal indeed 
corresponds to high molecular weight complexes such as HDLs.  
 
Fig. 3.11: High density lipoproteins elute 
close to the void volume when serum is 
subjected to SEC on Superdex 75.  
Upper panel: Elution profile from SEC on a 
HiLoad 26/60 Superdex 75 column; UV-
absorption at 280nm (y-axis) is given, the 
elution volumes are normalized for the 
void volume of the column (V0, = 
105ml).running conditions for all runs: 4°C, 
2,5ml/min, running buffer: 1×PBS.  
Lower panel: western blot of SDS-PAGE 
from the elution fractions. 10µl of each 
fraction were separated by SDS-PAGE and 
blotted onto nitrocellulose; first antibody: 
mouse anti human ApoA1. Sizes of the 
molecular weight marker are indicated.  
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Flotation by ultracentrifugation 
The different lipoproteins present in the serum differ by their relative density 117. This 
feature can be used for their separation. If the density of a solution is adjusted to the density 
of the lipoproteins of interest, ultracentrifugation will lead to the flotation of these particles.  
Peak fractions from the S75 column were pooled, adjusted to  the density of HDLs 
(1,121g/cm3) using sodium bromide and subjected to ultracentrifugation. Analysis of the 
gradient fractions by coomassie-stained SDS-PAGE and WB showed that the ApoA1-signal 
was enriched in the top fractions after ultracentrifugation (fig. 3.12). This step therefore led 
to a further purification of the HDLs from other serum proteins. The presence of other 
protein contaminants in the top fractions after ultracentrifugation, made an additional step 
necessary.  
 
 
 
Separation on a Superose 6 column 
In order to further purify the obtained HDL and to separate them from the sodium bromide, 
the pooled top fractions from ultracentrifugation were concentrated and applied onto a 
HR30/100 Superose 6 column. The elution profile of this run showed a clear peak at a Ve/V0-
ratio of 1,30 (fig. 3.13 A); in these fractions, a marked band of ~25 kDa was visible in the 
coomassie-stained SDS-PAGE (fig. 3.13 B). Eluting much earlier than free ApoA1 would have 
(expected Ve/V0-ratio: ~2,0), this peak was likely to correspond to HDLs.  
Fig. 3.12: HDLs float up in 
ultracentrifugation at a 
density of 1,121g/cm
3
. 10µl of 
each fraction after 
centrifugation were applied 
onto a SDS-PAGE which was 
either coomassie-stained (A) 
or blotted onto nitrocellulose 
(B). First antibody: mouse α 
human ApoA1. Sizes of the 
molecular weight markers are 
indicated. 
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Fig. 3.13: SEC on Superose 6 as third purification step leads to a concentrated and pure HDL-preparation.  
A: Elution profile from SEC on a HR 30/100 Superose 6 column; UV-absorption at 280nm (y-axis) is given, the 
elution volumes are normalized for the void volume of the column (V0, =8ml).running conditions for all runs: 
4°C, 0,4ml/min, running buffer: 1×PBS.  
B: Coomassie-stained SDS-PAGE of the elution fractions from A and of pooled peak fractions. Sizes of the 
molecular weight markers are indicated in kDa.  
 
Next, peak fractions from the Superose 6-elution were pooled and concentrated. When a 
sample of this concentrate was analyzed by coomassie-stained SDS-PAGE (fig. 3.13B, right 
lane), several other bands were also visible besides the prominent ApoA1-band. Since HDLs 
contain ApoA-II (17 kDa), ApoA-IV (44 kDa), ApoC-I-III (6,6 kDa, 8,9 kDa and 8,8 kDa, 
respectively) ApoD (22 kDa) and ApoE (10 kDa), some of these bands may be attributed, 
although not with certainty, to HDLs.  
Quantification of the protein content in the pooled fraction revealed a concentration of 
1,97mg/ml. In human plasma, ApoA-I has a concentration of 1,3mg/ml. The purification 
method therefore led to a 1,5-fold enrichment of the HDLs. Having reached a satisfying 
purity, these HDLs were used for subsequent analyses. 
3.1.4.2 HDL bound HBV preS derived lipopeptides depending on their N-terminal moiety 
In the following experiment, a C14- a C18-acylated or a cholesteroylated peptide with wt 
sequence were preincubated with HDLs and subjected to SEC. The purified HDLs eluted as a 
clear peak when subjected to SEC on a Superose 6 column (fig. 3.14, black curve) at a Ve/V0-
ratio of 1,60. This ratio differed slightly from the one observed during purification of the 
HDL; this is probably due to usage of a different Superose 6 column, as these show slight 
variations in their separation behavior. Small peaks eluting in later fractions might either be 
B A 
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co-purified contaminants or HDL protein constituents that had dissolved from the 
lipoproteins.  
When a myristoylated preS-peptide was preincubated with HDLs and subjected to SEC, only 
a small amount of peptide shifted to an earlier elution volume (fig. 3.14, red curve). A 
stearoylation on the peptide´s N-terminus conferred stronger binding, the largest part of the 
peptide-signal having shifted to earlier elution volumes (fig. 3.14, blue curve). When the 
assay was performed with a preS-peptide carrying a cholesterol-moiety, however, the entire 
peptide was bound to HDLs (fig. 3.14 green curve). 
 Fig. 3.14: The N-terminal moiety determines the binding to HDLs. 100µl of purified HDLs were preincubated 
either with buffer (black curve) or with 50µM of HBVpreS/2-48
myristoyl 
(red curve), HBVpreS/2-48
stearoyl 
(blue 
curve) or HBVpreS/2-48
cholesteroyl 
(green curve) for 1h at 37°C and subjected to SEC. Elution profiles from SEC on 
a HR 30/100 Superose 6 column; UV-absorption at 280nm (left y-axis) and 490nm (right y-axis) are given, the 
elution volumes are normalized for the void volume of the column (V0, =8ml). Running conditions for all runs: 
4°C, 0,4ml/min, running buffer: 1×TN. Representative data of 2 independent experiments are shown.  
 
Although ApoA1 has been identified as binding partner using a myristoylated preS-peptide, 
the weak interaction between HDL and preS/2-48myristoyl observed here may be due to the 
different assay conditions. In the crosslinker-assay, formed complexes are stabilized by 
formation of covalent bonds. In the SEC-assay, weak complexes formed by hydrophobic 
interactions only dissociate more easily.  
However, as seen for the peptide-HSA-interaction, the hydrophobicity of the N-terminal 
moiety influences the binding to HDL, the strongest binding being observed for a 
cholesteroylated peptide.  
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3.1.5 Neither HDL nor HSA influenced peptide binding to primary hepatocytes 
HBV preS peptides have been shown to bind to a wide range of primary hepatocytes 64, a cell 
type involved in metabolism of fats and fatty acids. While the existence of a specific receptor 
for albumin is a subject of discussion, the role of albumin in binding and uptake of fatty acids 
into hepatocytes has often been postulated (introduction chapter 1.6.2). HDLs are known to 
bind via ApoA1 to the scavenger receptor B1 (SRB1) 133 and thereby get taken up by the cell. 
The finding that HBV preS peptides bind to serum albumin and HDLs raised the question 
whether these interactions influence peptide binding to hepatocytes.  
In this assay, radiolabeled wt preS-peptide was incubated with freshly isolated primary 
mouse hepatocytes (PMH). Thereafter, the supernatant 60 was taken off, the cells washed 
three times with PBS and lysed with NaOH. Radioactivity of all fractions was measured. 
Before incubation, cells were thoroughly washed to remove secreted proteins. The 
incubation itself was performed in serum-free medium in the absence or presence of HSA, 
HDLs or a combination of both. All assays were done in triplicates, using one peptide-
mastermix. 
After incubation, the SN of the cells contained ~5×105 cpm (fig. 3.15, peptide only, black 
bars) or ~7×105 cpm when HSA or HDL were added (fig. 3.15, grey bars). This difference was 
not statistically significant (p>0,05). With each washing step, radioactivity decreased, 
showing slight, but not significant differences; the final cell pellet then contained ~3×104 
cpm (peptide only) or ~2-3×104 cpm (peptide + HSA/HDL). Therefore, addition of either 
substance or combination of both did not influence peptide binding to PMH. 
 
Fig. 3.15: HSA and HDL do not 
influence peptide binding to 
PMH. 165 nM 
125
I-labeled 
preS/2-48
myr
 -y49 were incubated 
in the absence or presence of 
25µM HSA and /or 1,8µM HDL in 
serum-free medium for 1h at 
37°C. SN was taken off, cells 
washed three times with PBS 
and lysed with 1N NaOH. All 
fractions were assessed for 
radioactivity in a γ-counter. 
Representative data of 2 
independent experiments.  
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3.1.6 Liver tropism was not impaired in a ApoA1-deficient mouse 
In order to assess whether the peptide binding to HDLs has an effect on the peptides´ liver 
tropism, radiolabeled myristoylated wt HBV preS-peptide was injected into a mouse 
deficient for Apolipoprotein A1. As control, a wildtype mouse was used. The lack of ApoA1 
expression was controlled by analyzing liver samples from both mice for ApoA1 content in 
western blot (fig. 3.16A). 
When comparing the radioactivity signal in the ApoA1 deficient mouse to the one in the wt 
mouse, no difference in liver tropism could be detected (fig. 3.16 B). While the signal at the 
site of injection was comparable in both mice, the signal in the liver was slightly increased in 
the ApoA1 deficient mouse. It can therefore be concluded that the peptide-HDL interaction 
has no positive effect on liver tropism.  
 
Fig. 3.16: The peptides´ liver tropism is not impaired in ApoA1 deficient mice. I
125
-labeled HBVpreS/2-48
myristoyl 
was injected subcutaneously into WT C57BL6 mice (left) or C57BL6/ApoA1(-/-) mice (right). Scintigraphic 
imaging was performed 8h after injection (B). Mice were then sacrificed; liver samples were taken and analyzed 
by mouse ApoA1-specific western blot (A).Mice were kindly provided by K. Matuschewski. 
3.1.7 Addition of HSA or HDL did not influence HBV infection 
In the previous experiments, the interaction of preS-peptides with HSA or HDL has been 
studied. In order to obtain a first hint whether a possible HBV-HSA or HBV-HDL interaction 
has an influence on HBV-infection, both substances were added to an HBV-infection assay on 
primary human hepatocytes (PHH) in the presence of fetal calf serum (FCS). 
When HSA was added to the infection assay, the amount of secreted HBsAg in the 
supernatant of day 7 to 12 increased by ~40% (fig. 3.17 A) in comparison to the control 
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infection. Inhibition of infection by wt preS-peptide reduced the HBsAg secretion to about 
the same level as when no albumin was added.  
Addition of purified HDLs lead to a decrease of infection by ~30% in comparison to the 
control infection (fig. 3.17 B). Again, the addition of preS-peptides reduced infection to 
control level. The observed effects are only moderate, neither HSA or HDL appeared to have 
a strong effect on HBV infection. The observation that infection inhibition was not altered 
confirms indirectly that neither factor has a role in binding of preS-peptides to hepatocytes. 
 
 
Fig. 3.17: Neither HSA nor HDL have an influence on HBV infection or infection inhibition. PHH were infected 
with a MOI of 1×10
4 
in the absence of inhibitor or presence of  500nM preS-peptide and absence or presence of 
120µM HSA (A) or 8µM HDL (B). Supernatants from day 7-12 were harvested, secreted HBsAg was measured by 
quantitative ELISA. Representative data of 3 independent experiments are shown.  
 
 
3.2 Attempts to identify a cellular interaction partner for HBV preS-peptides 
It could be shown that His-tagged HBV preS-peptides containing an aryl azide-moiety 
(crosslinker-peptides) could efficiently be used for identification of binding partners in 
human serum (chapter 3.1.1.3). It was therefore assessed whether these peptides would 
also allow identification of a receptor molecule on hepatocytes.  
Therefore, primary hepatocytes from rats were isolated and incubated with either acylated 
wt CL-peptide, acylated mutant CL-peptide, non-acylated wt CL-peptide or no peptide for 1h 
at 4°C. Following UV-light exposure, cells were lysed, suspensions were separated from cell 
debris and subjected to affinity chromatography on a nickel-sepharose column.  
Fig. 3.18 shows a typical elution profile from this assay when performed with WT peptide. 
During application of the sample, the UV-absorption (fig. 3.18, blue curve) rose sharply and 
remained above detection limit. The column was then washed with 5% of the high-imidazole 
A B 
Results 
 
 
69 
elution buffer (fig. 3.18, red curve). This led to a relatively high UV-absorption, being caused 
by unspecifically bound material being washed off. Subsequent elution was performed in 
three steps: a flat linear gradient over 10 column volumes 2 from 5% to 50% elution buffer, 
leading to elution of weakly bound molecules; a sharper linear gradient over 5CV from 50% 
to 100% elution buffer, causing elution of strongly bound substances; and a high-imidazole 
wash over 10CV at 100% elution buffer. Monitoring of conductivity  (fig. 3.18, green curve) 
gave information about the actual increase of the high-salt elution buffer during the elution.  
 
 
 
When elution profiles from these assays performed with the different peptides were 
compared, no remarkable differences could be observed. The first two large peaks from the 
column wash and the first linear gradient step appeared in all elution profiles. At the second 
linear gradient step, however, a shoulder could be detected in the wt-elution profile but not 
in any of the other elution profiles (fig. 3.19).  
Fig. 3.18: Affinity chromato-
graphy of an incubation of wt 
crosslinker peptide with 
primary rat hepatocytes. 
30ml lysate from cells 
preincubated with 1µM HBV 
preS/2-48
myristoyl
-CL were 
applied onto a 1ml Ni
2+
 -
column; after a low imidazole 
wash, bound proteins were 
eluted with a 2-step linear 
imidazole gradient. During the 
run, UV-absorption at 280nm 
and conductivity were 
monitored.  
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Fig. 3.19: Comparison of the elution profiles from crosslinker assays on primary rat hepatocytes. 30ml lysate 
from cells preincubated with 1µM HBV preS/2-48
myristoyl
-CL, 1µM preS/2-48 (Ala 11-15)
myristoyl
-CL , 1µM preS/1-
48-CL or no peptide were applied onto a 1ml Ni
2+
 -column; after a low imidazole wash, bound proteins were 
eluted with a 2-step linear imidazole gradient. A detail of overlay from the second step is shown.  
 
Elution fractions from these chromatography runs were then analyzed by HBV preS1-specific 
wb for preS peptide-protein complexes.  
Western blots for crosslinker-assay with wt-, mutant and non-acylated peptides are shown in 
fig. 3.20. For more clarity, elution profiles are overlaid in the wb.  
A large amount of protein eluted during the first linear gradient step, visible as background 
stain in all three wb. In the fractions corresponding to the shoulder in the second linear 
elution step, a low-molecular weight band (~15 kDa) was visible in the wb for wt (fig. 3.20 
A), but not in the wb for acylated mutant (fig. 3.20 B) or non-acylated peptide (fig. 3.20 C). 
Attempts to identify the proteins of this band, however, did not yield results.  
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In summary, no cellular interaction partner for HBV preS1-derived peptides could be 
identified.  
  
Fig. 3.20: Western blots of elution 
fractions from crosslinker-assays 
with wildtype (A), acylated mutant 
(B) or non-acylated peptide (C). 
Samples of each elution fraction 
were applied onto a 12% Lämmli-gel 
and blotted onto nitrocellulose. 
Complexes of preS-peptides to 
cellular proteins were detected by 
using a HBV preS1-specific antibody 
(Ma18/7).  
 
A 
B 
C 
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3.3 Membrane activity of HBV preS-derived peptides 
HBV infection has been shown to depend on the presence and intactness of the HBV L-
protein preS1-domain 20 and on its N-terminal acylation 28, 42. Until now, it is unclear how 
HBV enters hepatocytes, a specific receptor has not been identified (introduction chapter 
1.2.6). A crucial step in the entry of enveloped viruses is uncoating. This usually occurs by 
fusion of the viral membrane with a host cell membrane, either the plasma membrane or an 
endosomal membrane. A role of the HBV preS-sequence in membrane fusion has been 
discussed recently 85. Using a set of preS-derived peptides well characterized for their ability 
to inhibit HBV-infection 62 and their binding to hepatocytes 64, we assessed these peptides´ 
membrane activity in a liposome-based leakage assay. Association to membranes was 
studied by a coflotation assay; electron microscopy studies of preincubated peptides with 
liposomes were performed to visualize a possible structural alteration.  
3.3.1 The liposome-based membrane activity assay 
Liposomes containing 8-hydroxypyrene-1,3,6-trisulfonic acid (HPTS), a fluorescent dye, and 
p-xylene-bis-puridinium bromide (DPX), a substance that quenches HPTS when present in 
high concentration, were used. Incubation with membrane active substances, such as 
detergents or membrane dissolving or channelizing proteins, leads to leakage of HPTS and 
DPX from the liposome, thereby dequenching of the HPTS and an increase of fluorescence 
(fig. 3.21). Here, membrane activity of the preS-peptides was analyzed. 
After addition of peptides to liposomes, plates were incubated at 37°C and emission on a 
HPTS-specific wavelength was measured. After incubation, detergent was added, leading to 
lysis of all liposomes, dequenching of all HPTS and maximal fluorescence signal. This 
absorption was set as 100%, values obtained during incubation were calculated as 
percentage of the lysis value. A schematic representation of this assay is given in fig. 3.21. 
This assay can be used in order to determine whether a peptide or protein exhibits 
membrane activity, i.e. whether it is able to perturb membranes in such a way that the 
membrane becomes permeable for small molecules. As such, it does not allow the 
conclusion that a peptide mediates fusion, since no conclusions on fusion of liposomes, but 
only on leakage of dye can be drawn.  
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Fig. 3.21: Principle of the membrane activity assay. Liposomes containing HPTS and DPX (in a concentration 
that quenches HPTS-fluorescence) are incubated with a membrane active substance. This substance leads to 
leakage of HPTS and DPX from the liposomes and therefore dequenching of HPTS. After incubation time, 
detergent is added in order to lyse all liposomes. During incubation, fluorescence is measured; the value 
obtained by detergent lysis is set as 100%.  
 
In all the following experiments, liposomes consisting of phosphatidylserine (PS) and 
phosphatidylcholine (PC) were used.  
 
3.3.1.1 The wildtype PreS-peptide showed a concentration-dependent membrane activity 
First, it was addressed whether a wt preS-peptide is membrane active. Therefore, increasing 
concentrations of a wt peptide were added to liposomes. Addition of 50 µM stearoylated 
wildtype peptide led to a ~9% increase in fluorescence over 120min (fig. 3.22, orange 
curve); this activity was found to increase at 100µM peptide (fig. 3.22, red curve). No 
leakage was observed when no peptide was added (fig. 3.22, green curve), indicating that 
the liposomes used here were stable under the chosen conditions. The HBV preS-peptide 
therefore exerts membrane activity in a concentration-dependent manner. 
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3.3.1.2 Membrane activity of preS depended on the integrity of the essential site 
Next, it was analyzed whether the correct sequence and the N-terminal acylation are 
required for the peptide´s membrane activity. Therefore, a peptide where 5 amino acids in 
the essential site had been replaced by their respective d-amino acids or a non-acylated 
peptide were used. Addition of the acylated mutant peptide did not lead to a significant 
increase in fluorescence (fig. 3.23, orange curve) nor was leakage observed when a non-
acylated peptide was added (fig. 3.23, blue curve). The essential site and the acylation are 
required for the peptide´s membrane binding and inhibitory activity, showing thus a strong 
correlation between infection inhibtion, membrane binding and membrane activity.  
 
 
Fig.3.22: Concentration-dependent 
membrane activity of preS-derived 
peptides. 50µM or 100µM wt 
peptide were incubated with 
liposomes (ca. 80µM lipid) consisting 
of 85% PS and 15% PC and 
containing HPTS/DPX , over 60 
minutes. At the end of the 
incubation period, lysis of all 
liposomes was induced by addition 
of 10µl 2,5% dodecyl maltoside. 
Representative data of 3 
independent experiments.  
 
Fig. 3.23: Perturbation of the 
essential site and removal of the 
N-terminal acylation led to loss 
of activity. no peptide or 50µM of 
each peptide were incubated 
with liposomes (ca. 80µM lipid) 
consisting of 85% PS and  15% PC 
and containing  HPTS/DPX , over 
60 minutes. At the end of the 
incubation period, lysis of all 
liposomes was induced by 
addition of 10µl 2,5% dodecyl 
maltoside. Representative data of 
2 independent experiments.  
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3.3.1.3 Deletions of the N-terminal amino acids were tolerated up to amino acid 7 
The N-terminus of the preS-peptide is required for its inhibitory activity; deletion are 
tolerated only up to aa 6 62. Therefore, the role of the preS-N-terminus in membrane activity 
was assessed. Peptides with N-terminal deletions up to aa 9 or a peptide with the 11 
additional amino acids from genotype B were used. Comparison of these peptides with 
regard to their membrane activity showed that peptides lacking 3 aa (fig. 3.24, yellow curve) 
or 5aa (fig. 3.24, dark blue curve) perturb membranes similar to wt peptides (red curve). 
Deletion of 7aa (fig. 3.24, pink curve) reduced fluorescence signal stronlgy. Interestingly, a 
peptide comprising the additional N-terminal 11 amino acids of genotype B (fig. 3.24, light 
blue curve) led to a marked increase in membrane activity, showing a five times increase 
compared to the 2-48 peptide. This is in contrast to infection inhibition by preS-peptides, 
where the additional 11 aa of genotype B did not increase infection inhibition 62 . Taken 
together, this indicates that the extreme N-terminal part of preS1 is involved in perturbation 
of lipid membranes. 
 
3.3.1.4 The N-terminal acylation required a minimal length for membrane activity 
Due to their hydrophobicity, acylations of proteins or peptides are often determinants for 
membrane interaction, being responsible for initial contact with membranes or targeting a 
protein to certain membrane compartments 134,135. The preS-acylation is therefore likely to 
play a role in the peptide´s membrane activity. The membrane activity assay was therefore 
performed with peptides carrying shorter acylations.  
Fig. 3.24: The extreme N-
terminus is required for 
membrane activity. 50µM of 
each peptide were incubated 
with liposomes over 60 minutes. 
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Incubation of liposomes with a C5- (fig. 3.25, orange curve) or C8-acylated preS-peptide 
(blue curve) did not raise the fusion signal over the background signal obtained when no 
peptide was added (fig. 3.25, green curve). A C14-acylated peptide (fig. 3.25, red curve) did 
induce leakage similar to values observed before for C18-acylated peptides.  
 
 
Also, the activity of a C14 and a C18-acylated peptide whose sequence corresponded to the 
consensus sequence from different HBV-genotypes was compared to the activity of the 
genotype D stearoylated wildtype, since the consensus-peptide shows an increased 
inhibitory activity in HBV-infection. Comparison of a C14- (fig. 3.26, blue curve) to a C18-
acylated peptide (fig. 3.26, green curve) showed an increase in fluorescence by ~7% with 
increasing acylation chain length. Interestingly, a stearoylated peptide with a consensus 
sequence from the different HBV genotypes (fig. 3.26, green curve) was more active than a 
stearoylated peptide with genotype D wildtype sequence (3.26, red curve).  
Fig. 3.25: The fatty acid 
chain length is essential 
for activity. 50µM of each 
peptide were incubated 
with liposomes over 30 
minutes. 
 
Fig. 3.26: The fatty acid 
chain length is essential for 
activity. 50µM of each 
peptide were incubated with 
liposomes over 60 minutes. 
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Taken together, it was shown that HBV preS-peptides were able to disturb phospholipid 
membranes depending on their sequence integrity and on the N-terminal acylation, which 
had to be of a minimal length. These features correlated with their ability to inhibit HBV 
infection and with their specificity in hepatocyte membrane binding, indicating a possible 
role in fusion of the viral membrane with a host cell membrane.  
3.3.2 After coincubation, preS-peptides showed coflotation with liposomes 
In order to assess whether the observed membrane activity of preS-peptides results from 
weak, transient interaction or is the result of a binding or insertion, coflotation assays were 
performed. Therefore, acylated wt, non-acylated wt or acylated mutant peptides were 
incubated with or without liposomes for 1h at 37°C. In a subsequent ultracentrifugation on a 
nycodenz-gradient, liposomes were floated; the usage of fluorescently labeled liposomes 
allowed a visual control of their flotation (data not shown). These gradients were then 
fractionated, the fractions were assessed for their peptide content in wb using a preS1-
specific antibody. As input control, input peptide was loaded.  
When wt peptide was incubated without liposomes, ultracentrifugation led to accumulation 
of all peptide signal on the bottom of the gradient (fig. 3.27 A, left panel). After addition of 
liposomes to the incubation, a part of the peptide signal was detectable on the top of the 
gradient, indicating coflotation of peptides with liposomes (fig. 3.27 A, right panel). 
Performing this assay with a non-acylated peptide did not lead to peptide flotation (fig. 3.27 
B); interestingly, an acylated mutant peptide did float up when incubated with liposomes 
(fig. 3.27 C).  
Fig. 3.27: Acylation-dependent, 
sequence independent binding 
of HBV preS-peptides to 
phospholipid liposomes.  
50µM of peptide and 640µM 
lipid or buffer were 
coincubated at 37°C for 1h. 
Subsequent ultracentrifugation 
on a nycodenz-gradient (40%-
30%-buffer) for 1h at 
380.000×g was followed by 
fractionation. All fractions were 
subjected to SDS-PAGE and 
transferred onto nitrocellulose-
membranes. HBVpreS-peptides 
were detected using a preS1-
antibody (Ma18-7). 
Representative data of 2 
independent experiments.  
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PreS-peptides therefore showed an acylation-dependent binding to liposomes which was 
strong enough to withstand the relatively harsh conditions of ultracentrifugation. This hints 
towards an insertion of the fatty acid and possibly a part of the peptide into the 
phospholipid membrane.  
3.3.3 HBV preS-peptides caused structural alterations in liposomes 
In order to analyze whether the membrane activity described above leads to disruption and 
alteration of liposomal membranes, increasing amounts of peptides were coincubated with 
liposomes and subsequently analyzed by negative stain electron microscopy. For reduction 
of staining background, liposomes were prepared in a low salt phosphate buffer; peptides 
were dissolved in the same buffer.  
Without the addition of peptide, liposomes of different sizes (100nm - 500nm) could be 
observed (fig. 3.28 A), appearing to some extent folded, but generally intact. When the 
incubation was done in the presence of 8µM wt peptide, very little membranous structures 
were left; instead, filamentous shapes associated with electron dense material could be 
observed (fig. 3.28 B). An increase of the peptide concentration to 16µM led to almost 
complete disappearance of intact liposomes, aggregations of electron dense material could 
be observed (fig. 3.28 C). These morphological changes could not be observed when 
liposomes were incubated with an acylated mutant (fig. 3.28 D) or a non-acylated peptide 
(fig. 3.28 E). At higher peptide concentrations, electron dense material was found to be 
associated to liposomes, but this did not seem to affect their structure.  
In conclusion, HBV wt preS-peptides appear to have a dose-dependent effect on liposomal 
integrity which is absent in mutant peptides.   
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Fig. 3.28: Sequence- and acylation dependent structural membrane alterations induced by preS-peptides. 
Liposomes (3mM lipid) were incubated without or with (8-16 µM) of acylated wildtype, non-acylated wildtype 
or acylated mutant peptides for 1h at 37°C. After adsorption onto pioloform-coated EM-grids, negative staining 
with 1% uranyl acetate was performed. Micrographs were taken on a Leica EM 900. Representative data of 3 
independent experiments. 
 
3.4 Analysis of HBV and HDV infection on Hepatocytes from different rodent 
species 
HBV is known to have a very restricted host range (see introduction chapter 1.2). This is 
generally assumed to be due to the specificity of the unknown HBV-receptor, thought to be 
present only in a small range of species. However, HBV infects primary hepatocytes from 
Tupaia belangeri 36, a tree shrew belonging to the order of Scadentia within the clade of 
Supraprimates which also comprises the Primates, the Rodentia (rodents) and the 
Lagomorpha (hares and rabbits). The fact that HBV preS-derived peptides bind to primary 
hepatocytes from different species within this clade raised the question whether other 
species can be infected with HBV. 
HDV is thought to share a common entry pathway with HBV; yet, since HDV is an RNA-virus 
replicating without DNA-intermediate, it is less likely to face restriction of replication once it 
successfully entered a cell. Therefore, analysis of HDV infection in the different species was 
included. 
Rats, rabbits, hamsters and guinea pigs were chosen as animals for preparation of primary 
hepatocytes that were then infected with either HBV or HDV. All infections were controlled 
by parallel infection in the presence of the inhibitory preS-peptide in order to assess 
specificity.  
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Furthermore, cells were infected with woodchuck-hepatitis delta virus (WHDV), a virus 
originating from an HDV-infection of woodchucks that were infected with woodchuck 
hepatitis virus (WHV) 128. WHDV therefore carries the envelope proteins from WHV. 
Belonging to the order of rodentia, woodchucks are phylogenetically close to rats, guinea 
pigs and hamsters.  
As read out, quantitative ELISA of secreted HBsAg and Immunofluorescence analysis (IF) was 
performed for HBV infections. The HDV-infections were assessed by IF only.  
All infection experiments were done twice; a parallel HepaRG infection, using one inoculum 
mastermix, was performed every time. 
3.4.1 HBV infection 
3.4.1.1 HBV preferentially infected differentiated HepaRG cells 
As it has been described before, differentiated HepaRG cells are susceptible to  HBV-
infection 38. IF analysis of infected HepaRG cells revealed a generally cytoplasmatic and less 
often nuclear distribution of the core antigen. Infection was clearly restricted to the so-
called "islands" of differentiated cells. Addition of 500nM HBV preS1-peptide led to a strong 
reduction in HBV-infection (fig. 3.29), as described by literature. 
 
Fig. 3.29: Infection of HepaRG cells with HBV. Differentiated HepaRG cells were inoculated with an multiplictiy 
of infection 
24
 of 10
4 
for 16h in the absence or presence of 500nM HBVpreS/2-48
myr
. On day 12 p.i., cells were 
fixed, permeabilized and stained for HBcAg. Representative data of 8 independent experiments. 
3.4.1.2 Primary hepatocytes from rat and rabbit were not susceptible to HBV infection 
Hepatocytes from rat (PRH) or rabbit (PRaH) were prepared as described in material and 
methods and infected on day 1 after isolation with HBV. Analysis of HBsAg in SN from day 7-
12 p.i. showed no secreted antigen in the case of either species (fig. 3.30).  
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Fig. 3.30: HBV infection of primary rat (A) or rabbit (B) hepatocytes. On day 1 after isolation, cells were 
infected for 16h with a MOI of 10
4 
in the absence or presence of 500nM HBVpreS/2-48
myr
. A control infection of 
HepaRG cells was done in parallel with an inoculum mastermix. SN of day 7-12 were harvested, secreted HBsAg 
was measured by ELISA and is expressed as percentage of control infection of HepaRG. Representative data of 
2 independent experiments. 
Immunofluorescence of these cells showed no HBcAg specific stain in cells from either 
species (fig. 3.31 and fig. 3.32), confirming the above results. It has to be mentioned that 
PRH were found to be very sensible to seeding density and were difficult to cultivate, 
detaching from plates or forming clumps within two days after plating. Due to this, focusing 
on a single cell layer in fluorescence microscopy proved to be challenging. 
 
 
 
 
Fig. 3.31: Infection of PRH with HBV. Freshly isolated PRH were inoculated with an MOI of 10
4 
for 16h in the 
absence or presence of 500nM HBVpreS/2-48
myr
. On day 12 p.i., cells were fixed, permeabilized and stained for 
HBcAg. Representative data of 2 independent experiments. 
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Fig. 3.32: Infection of PRaH with HBV. Freshly isolated primary rabbit hepatocytes were infected with an MOI 
of 10
4 
for 16h in the absence or presence of 500nM HBVpreS/2-48
myr
. On day 12 p.i., cells were fixed, 
permeabilized and stained for HBcAg. Representative data of 2 independent experiments. 
 
3.4.1.3 Primary hepatocytes from hamster and guinea pig showed susceptibility to HBV 
Interestingly, infection of primary hepatocytes from hamster (PHaH) and guinea pig (PGH) 
led to secretion of HBsAg into the supernatant of day 7-12 after infection (fig. 3.33). 
Infection of PHaH led to secretion levels reaching ~80% of the HepaRG control infection and 
could be reduced by addition of preS/2-48myristoyl to ~15%. Infection of PGHs led to HBsAg 
levels of ~60% of the control infection; on these cells, infection could not be inhibited with 
the peptide.  
 
 
This observation could be confirmed by immunofluorescence against HBcAg (fig. 3.34). The 
typical cytoplasmatic staining, forming either speckles or being equally distributed, was 
detectable in cells from both species. Only few infected cells could be detected in the PHaH-
infection when the preS-peptide was added.  
 
Fig. 3.33: HBV infection of primary 
hepatocytes from hamster (light grey 
bars) or guinea  pig (dark grey bars). On 
day 1 after isolation, cells were infected 
for 16h with a MOI of 10
4 
in the absence 
or presence of 500nM HBVpreS/2-48
myr
. 
A control infection of HepaRG cells was 
done in parallel with an inoculum 
mastermix. SN of day 7-12 were 
harvested, secreted HBsAg was 
measured by ELISA and is expressed as 
percentage of control infection of 
HepaRG. Representative data of 2 
independent experiments. 
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Fig.3.34: Infection of PHaH or PGH with HBV. Freshly isolated primary hepatocytes from hamster (A) or guinea 
pig (B) were infected with an MOI of 10
4 
for 16h in the absence or presence of 500nM HBVpreS/2-48
myr
. On day 
12 p.i., cells were fixed, permeabilized and stained for HBcAg. Representative data of 2 independent 
experiments. 
 
3.4.2 HDV infection 
3.4.2.1 Infection of HepaRG with HDV led to typical nuclear staining 
When inoculated with serum from HDV-infected patients, HepaRG cells got infected with 
HDV. Immunofluorescence staining against the HDAg led to a typical nuclear staining which 
is due to the HDsAg present in the nucleus where it promotes replication (introduction 
chapter 1.5.4). This HDV infection could be inhibited with the preS-peptide (fig. 3.35). 
HepaRG cells also proved to be susceptible to infection with the Woodchuck HDV. This 
infection could not be inhibited by addition of the HBV preS1-derived peptide. In the WHDV-
infection, the HDAg accumulated preferentially in the nucleus; an occasional cytoplasmatic 
stain could be observed.  
 
B 
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Fig. 3.35: Infection of HepaRG cells with HDV and WHDV. Differentiated HepaRG cells were inoculated with 
serum from a HDV-positive patient or serum from WHV-HDV-infected woodchucks for 16h in the absence or 
presence of 500nM HBVpreS/2-48
myr
. On day 5 p.i., cells were fixed, permeabilized and stained for HDAg. 
Representative data of 2 independent experiments. 
 
3.4.2.2 Primary rat hepatocytes are not susceptible to HDV but to WHDV 
When PRH were incubated wit HDV-positive serum, no infection could be detected by IF (fig. 
3.36). A high background staining was often visible, forming blot-like dots between cells. 
Since no specific nuclear staining was observed, this was not regarded as HDV-infection. 
However, these cells were susceptible to WHDV infection. 
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3.4.2.3 Primary rabbit hepatocytes could be infected with HDV at a low rate 
Inoculation of PRaH with HDV led to a positive staining in IF (fig. 3.37), yet only very few cells 
were found to be infected. This infection was found to be sensitive to inhibition by the preS-
peptide, since no infected cell could be detected in cells treated with HDV and preS-peptide. 
PRaH cells could also be infected with WHDV; addition of the preS-peptide did not lead to 
abrogation of WHDV infection.  
Fig. 3.37: Infection of PRaH with HDV 
and WHDV.  
PRaH cells were inoculated on day 1 
after plating with serum from a HDV-
positive patient or serum from WHV-
HDV-infected woodchucks for 16h in 
the absence or presence of 500nM 
HBVpreS/2-48
myr
. On day 5 p.i., cells 
were fixed, permeabilized and 
stained for HDAg. Representative 
data of 2 independent experiments. 
Fig. 3.36: Infection of PRH with 
HDV or WHDV. PRH cells were 
inoculated on day 1 after plating 
with serum from a HDV-positive 
patient or serum from WHV-HDV-
infected woodchucks for 16h in the 
absence or presence of 500nM 
HBVpreS/2-48
myr
. On day 5 p.i., cells 
were fixed, permeabilized and 
stained for HDAg. Representative 
data of 2 independent experiments. 
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3.4.2.4 Primary hamster hepatocytes and primary guinea pig hepatocytes were not 
susceptible to HDV but could be infected with WHDV 
Infection of PHaH with HDV did not lead to any detectable positive staining (fig. 3.38). A 
background staining as described for PRH was found; its blot-like appearance, however, did 
not convincingly look like infected cells. PHaH were found to be susceptible to WHDV 
infection, although this resulted in a relatively weak, dot-like cytoplasmatic staining. Since 
this stain was always associated to nuclei and in the focal plane, it was seen as real infection. 
As for PRaH, WHDV infection could not be inhibited by addition of the preS-peptide.  
The same was shown for HDV and WHDV infection of PGH (fig. 3.39). Again, background 
staining was observed in the case of HDV-infection. WHDV led, as for PHaH, to cytoplasmatic 
staining in infected cells.  
 
 
 
Fig. 3.38: Infection of PHaH with 
HDV and WHDV.  
PHaH cells were inoculated on day 
1 after plating with serum from a 
HDV-positive patient or serum 
from WHV-HDV-infected 
woodchucks for 16h in the 
absence or presence of 500nM 
HBVpreS/2-48
myr
. On day 5 p.i., 
cells were fixed, permeabilized 
and stained for HDAg. 
Representative data of 2 
independent experiments. 
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The data from all infection experiments are summarized in table 3.1.  
 
Tab. 3.1: Summary of infection experiments on primary hepatocytes from different species.  
HBV: hepatitis B virus. HDV: hepatitis delta virus. WHDV: woodchuck hepatitis delta virus.  + : infection or 
inhibition of infection;  - : no infection or no inhibition of infection, respectively.  
 rat rabbit hamster guineapig 
HBV - - + + 
inhibition by 
preS-peptide 
- - + - 
HDV - + - - 
inhibition by 
preS-peptide 
- + - - 
WHDV + + + + 
inhibition by 
preS-peptide 
- - - - 
 
 
 
 
 
Fig. 3.39: Infection of PGH with 
HDV and WHDV.  
PGH cells were inoculated on day 
1 after plating with serum from a 
HDV-positive patient or serum 
from WHV-HDV-infected 
woodchucks for 16h in the 
absence or presence of 500nM 
HBVpreS/2-48
myr
. On day 5 p.i., 
cells were fixed, permeabilized 
and stained for HDAg. 
Representative data of 2 
independent experiments. 
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4. Discussion 
4.1. Binding partners for HBV preS-peptides in serum 
4.1.1 PreS-peptides bind serum factors in an acylation-dependent manner  
Biodistribution studies on HBV preS-derived peptides revealed their marked stability in 
serum and rapid targeting to the liver 63. The retention in the body was shown to depend on 
the N-terminal acylation, whereas the liver specificity required the intact peptide sequence, 
especially the essential domain aa 9-15. This led to the assumption that serum factors 
binding preS-peptides exist, preventing their excretion and possibly mediating binding to 
liver cells. 
In this work, the association of preS-peptides with serum factors was demonstrated and 
analyzed by a size exclusion chromatography (SEC) based assay. SEC has been shown to be 
an appropriate tool to study protein-protein interactions or interaction of small molecules 
with serum components136. It is therefore a valid assay for the question addressed here. 
In this work, it was observed that FITC-labeled preS-peptides showed a size shift when 
preincubated with serum, indicating their binding to a serum factor. The detection of only 
one shifted FITC-specific peak suggested binding mainly to one serum protein. The observed 
size shift can be attributed to the peptide and does not result from a FITC-dependent serum 
factor binding, since a non-acylated FITC-labeled peptide did not show an altered elution 
behavior (fig. 3.2 C). Furthermore, western blot analysis of elution fractions from a 
preincubation of peptide with albumin showed that peptide can be detected in albumin-
peak fractions (fig. 3.7), arguing for a binding of the authentic preS-peptide. 
 
4.1.2 Identification of albumin and apolipoprotein A1 as binding partners for preS-peptides 
Subsequently, crosslinker-peptides (CL-peptides) were used to identify binding partners for 
preS-peptides in human serum. The alterations introduced into these peptides did not 
modify their ability to inhibit HBV infection. They could be shown to be active in HBV 
infection inhibition in a sequence-dependent manner (fig. 3.3). 
When an unaltered preS-peptide (IC50 of 400 pmol) is added in increasing amounts to an 
HBV-infection, the secreted S-antigen decreases to below background level 62; the wt CL-
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peptide showed an inhibition ability similar to the unaltered wt peptide. Addition of higher 
concentrations of the wt CL-peptide did not reduce infection further; this is possibly due to 
an abreaction of the aryl azide moiety with primary amines in the cell supernatant during 
incubation. While an unaltered peptide diffuses to the cell surface during incubation, a 
fraction of the CL-peptide might react off unspecifically after a certain time and would then 
not be at disposition anymore.  
Addition of the mutant CL-peptide led to an apparent increase in HBV-infection. The reason 
for this is unknown. 
These CL-peptides were then used for identification of interaction partners from human 
serum.  
Photoactiveable crosslinker molecules have been shown before to be an efficient tool for the 
identification of interaction partners.  
Introduction of a phenylalanine with a trifluoromethyl-diazirin-moiety (TMD-Phe) into 
preprolactin was shown to allow its crosslinking to different proteins of the endoplasmatic 
reticulum 137. Others have described the usage of this modified phenylalanine for 
crosslinking of a transmembrane peptide to lipids 138. Photo-crosslinking is therefore a useful 
method for identification of different interaction partners. 
In this work, the CL-peptides allowed identification of two interaction partners in human 
serum. For both acylated wt CL-peptide and mutant CL-peptide, HSA and Apolipoprotein A1 
were found crosslinked to preS-peptides (fig. 3.4). No binding to serum components was 
found when the non-acylated wt peptide was used. In the elution fractions for the acylated 
peptides, HSA could be seen as background stain in the wash fraction (fig. 3.4); whereas the 
preS-peptide-HSA complex eluted later. Although the western blot and silver stain allowed 
no absolute quantification of bound and unbound HSA, it can be concluded that the larger 
part of HSA remained unbound. The input molar ratio HSA : peptide in this assay was ~ 4:1, 
therefore, a proportion of HSA was expected to be unbound.  
The ratio of peptide-HSA-complex to peptide-ApoA1-complex appeared to be ~1:1; ApoA1 is 
present in serum with ~54µM; therefore, the HSA : ApoA1 : peptide ratio was 12:1:3. This 
hints towards a higher affinity of preS-peptides for ApoA1 than for HSA. 
In contrast to this are the observations from SEC of peptides preincubated with serum. 
While a large part of the peptide signal shifted to overlap with the HSA-peak, no FITC-signal 
could be detected in fractions corresponding to uncomplexed ApoA1 or to HDL. 
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Both interactions were confirmed by the SEC-assay (fig. 3.5, 3.14); albumin-binding was 
confirmed with albumin or serum from other species (fig. 3.10). 
4.1.3 The affinity for HSA increases with the fatty acid chain length 
The HSA-binding was shown to increase with the length of the N-terminal fatty acid (fig. 3.6). 
While neither a C5- nor a C8-acylated peptide bound in the SEC-assay, C12-acylation 
conferred partial binding. The relative broadness of the bound peptide-peak and its tailing 
out indicates that dissociation of C12-acylated peptide from HSA during the SEC occured, 
indicating a rather low affinity. C14-, C18-acylated peptides and a cholesteroylated peptide 
were all completely bound. A C12-acylated peptide bound with a maximal amount of 0,3 
peptides per HSA-molecule (Kd = 63µM), C14-acylated peptides bound with a Kd of 18µM and 
with maximally 1 peptide /HSA-molecule. Analyzing the binding of C18-acylated preS 
revealed a maximal amount of 10 peptides per HSA-molecule (fig. 3.9).  
Short fatty acids such as octanoic acid (C8) are known to bind HSA with rather low affinity (Kd 
~1 µM) at two distinct binding sites on the molecule 139. For C12- and C14- fatty acids, 7 
common binding sites have been described 121. For myristic acid 120 and stearic acid (C18) 126, 
dissociation constants of 460nM and 14nM, respectively, have been reported. Peng and 
colleagues studied the binding of cholesterol to HSA and reported a rather high dissociation 
constant of 400µM and one binding site per HSA-molecule 140. No reports on the binding of 
acylated peptides to albumin are known. 
As the Kd-values reported for fatty acids are lower than those found in this work for acylated 
peptides, it is obvious that the hydrophilic peptide part decreases the peptides´ affinities for 
HSA. This explains why peptides with short acylations (C5, C8) do not bind HSA, while the 
short fatty acids themselves are known to bind albumin.  
For larger HSA-ligands, different dissociation constants have been reported. Short cationic 
antimicrobial peptides have been shown to bind HSA with Kd in the range of 4.3 - 22,2µM 
130. 
The Kd-values reported here lie in the range of 18-63µM and are therefore in accordance 
with values for large ligands. This suggests that preS-peptides do not bind on one of the 
smaller fatty acid binding sites, but rather to one of the two larger ligand sites. The overall 
hydrophobicity of the molecule is the critical feature in this step, arguing for Sudlow site I as 
the binding site for preS-peptides. In order to assess this in more detail, however, structural 
analysis or probe displacement studies would be necessary. 
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An important point is the difference in the binding of C14- and C18-acylated preS-peptides 
observed here. The C14-acylated peptide binds with a Kd of 17µM and a maximum of 1 
molecule per molecule HSA (fig. 3.9). In contrast, the C18-acylated peptide was calculated to 
have a maximal number of 10 binding sites and a Kd of 280µM. These Kd-values are in 
discrepancy with the values reported for fatty acids alone, where C18-FA bind with a ~10 
times higher affinity than C14-FA. One possible explanation is the existence of a low-affinity, 
unspecific secondary binding of the C18-aclyated peptide to HSA in addition to specific 
binding. A possible way to analyze this would be the incubation of HSA with increasing 
amounts of unlabeled C18-peptide in the presence of a constant amount of FITC-labeled 
C18-peptide; subsequent SEC would show whether the specific binding of 1 molecule 
peptide exists after saturation of unspecific binding. 
Another possible reason for the large number of C18-peptide binding sites might be an 
allosteric enhancing effect on binding by the peptide itself. Chuang and coworkers have 
analysed the effect of fatty acids on drug binding by HSA 124. Using a photoreactive 
radiolabeled probe, they showed that addition of long chain fatty acids has competitive and 
allosteric effects on probe binding, regulating HSA-binding in a very complex manner. It is 
possible that the C18-acylated peptide has an enhancing effect by binding secondary sites 
that cannot be reached by the C14-acylated peptide, thus leading to low affinity binding of 
additional peptides. 
 
4.1.4 PreS-peptide binding to albumin takes place in vivo 
The peptide-albumin interaction could be shown to take place in vivo in beagle dogs (fig. 
3.8). 10 minutes after intravenous injection of radiolabeled peptide, 75% of the injected 
dose was found in the liver; this value was stable over 1h (A. Schieck, unpublished data). 10 
min and 1h after injection, the preS-peptide was found bound to albumin when serum was 
subjected to SEC. The detected radioactivity was in the same order of magnitude at both 
time points and corresponded to ~ 10% of the injected dose. This argues for a relatively 
stable albumin-binding that keeps the peptide in the serum and prevents it from 
degradation.  
4.1.5 Does the albumin binding influence liver tropism or binding to hepatocytes? 
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The role of HSA binding in liver tropism of preS-peptides could not be studied directly, since 
no animal model being deficient in albumin or expressing low albumin levels was accessible. 
Therefore, indirect arguments for the role of HSA in liver tropism have to be taken into 
account. 
First, mutant peptides also bind HSA but are not targeted to the liver. Non-acylated peptides 
do not bind HSA and are rapidly excreted from the body (fig. 3.5; 63). This argues against a 
role for HSA-binding in liver tropism. 
Another argument is the finding that the addition of 300mg/ml β-cyclodextrin to the 
peptide-HSA preincubation did abolish the peptide-albumin interaction in SEC, but it has no 
influence on liver tropism of the peptide (data not shown, personal communication A. 
Schieck). The cyclodextrin bound the peptide more strongly than HSA did, but did not alter 
its biodistribution. In this case, another molecule has taken over the stabilizing role without 
affecting liver tropism. 
An influence of the HSA-peptide interaction onto hepatocyte binding could not be detected 
in this work. This was assessed by adding HSA to an incubation of preS-peptides on primary 
mouse hepatocytes (fig. 3.15). Neither was an altered amount of peptide found in the 
supernatant after incubation, nor were peptide amounts in wash fractions or cellular 
fractions influenced by HSA. It has to be mentioned, however, that the albumin 
concentration used here (25µM) was ~20 times lower than the physiological concentration 
(500µM). This concentration was chosen to match the HSA : peptide ratio of the SEC-assay 
while keeping the amount of input radioactivity as low as possible. Higher albumin 
concentrations might yield different results.  
A striking discrepancy exists between these in vitro data and the in vivo biodistribution study 
in beagle dogs mentioned above. While only 1% of the peptide was bound to hepatocytes 
after 1h incubation in vitro (fig. 3.8), 75% of the peptide was in the dog liver already 10min 
after intravenous injection (A. Schieck, unpublished data). This discrepancy is unlikely to be 
due to an unknown serum factor, since none other could be identified by the two 
independent assays in this work (SEC-shift assay and crosslinker- fishing experiment). Nor 
can saturation be the reason; the concentration chosen for the in vitro assay (165nM) lies 
within the range where no saturation of peptide binding to hepatocytes was detected (up to 
3,2µM) 64. It is more likely that this difference is due to the in vitro situation; the isolation 
procedure itself stresses the hepatocytes, leading to partial dedifferentiation 141As 
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dedifferentiation of primary hepatocytes leads to loss of peptide binding 64, the use of 
isolated hepatocytes might lead to decreased peptide binding compared to an in vivo assay. 
Concerning albumin-mediated binding and/or uptake of different substances by the liver, 
many controversial reports have been made. Until now, it is still under debate how the 
dissociation of the fatty acid from albumin and the entry into the target cells occurs. First 
studies on an albumin receptor have been performed by Weisiger and colleagues 142. 
Observing a saturable binding of oleate in perfused rat livers only when albumin 
concentrations rose with the oleate concentrations, they postulated a saturable receptor for 
the albumin-oleate complex on hepatocytes. This receptor was thought to be present with 
~107 binding sites per cell. This was questioned by Stollman and coworkers 143 who injected 
bilirubin in a perfused rat liver in absence or presence of albumin and monitored uptake and 
biliary excretion of the bilirubin. Observing an unaltered uptake speed in all conditions, they 
argued against a specific carrier-protein. Many further studies on the uptake of fatty acids or 
other HSA-ligands by the liver have been performed in the past decades. Some state that the 
hepatic uptake of HSA ligands is not altered by the presence of albumin 144; 145. Others tried 
to show that albumin does indeed alter the uptake kinetics 146 or that there exists a receptor 
for polymerized albumin 147; 148. Reed and colleagues 149 described a two-phase binding 
profile of albumin onto hepatocytes, consisting of a saturable- and a non-saturable 
component; They deduced 3,9×106 high-affinity binding sites per cell and a dissociation 
constant of 1,9 µM. As conclusion, they proposed that membrane-glycoproteins on the 
hepatocytes bind albumin and induce a conformational change in the molecule, thereby 
facilitating the delivery of albumin transported ligands. A cell surface-induced 
conformational change in the albumin was also postulated to reduce the affinity for its 
ligand 150. A rather recent theory claims a role for the unstirred water layer on hepatocytes 
in fatty acid uptake, saying that the presence of serum albumin would alter this layer and 
thereby facilitate fatty acid uptake into hepatocytes 151. Taken together, no direct evidence 
for an albumin receptor has been given yet, and the role for HSA in uptake of its ligands by 
the liver is unclear.  
In 1979, Hansson and colleagues 152 described a receptor for polymerized albumin on HBsAg-
particles. After coating microtiter plates with polymerized albumin, they studied binding of 
HBsAg-particles isolated from a patient and deduced albumin as receptor for HBV on the 
hepatocyte surface. This interaction has not been confirmed since.  
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Several groups reported interaction of albumin with the HBV preS2-sequence. A receptor for 
polymerized albumin on an HBsAg polypeptide was suggested 153. Krone and coworkers 
described binding of monomeric HSA to HBsAg-particles via the preS2-domain 154; 
polymerized HSA was thought to mediate binding between virus-like particles and 
hepatocytes by binding to the preS2-domain and to the liver cell surface 155. Since then, the 
preS2-domain has been shown convincingly to play no role in HBV infection 40; it is therefore 
unlikely that an interaction of preS2 with albumin plays a role in HBV entry.  
 
4.1.6 Apolipoprotein A1 was identified as binding partner for HBV preS-derived peptides 
ApoA1 is the major protein constituent of high density lipoproteins, complexes of 
triglycerides, phospholipids and cholesterol esters. It is present in the blood at a 
concentration of ~50µM. 
Using the CL-peptides described above, ApoA1 was identified as interaction partner for HBV 
preS-peptides (fig. 3.4). These bound ApoA1 to an approximately equal amount as they 
bound HSA, although albumin is present in a 12 fold higher concentration in serum. 
HDL could efficiently be purified from human serum by SEC (fig. 3.11, 3.13) and density 
adjusted ultracentrifugation (fig. 3.12), yielding a preparation with ~1,9mg/ml (80µM) 
containing almost no contaminating proteins. Optimisation of the purification protocol 
might be possible, especially at the ultracentrifugation step. Analysis of the coomassie-stain 
of fractions (fig. 3.12) showed that a signal of the correct size (24kDa), although weaker than 
in the top fraction, was also detected in lower fractions. The flotation of HDLs was therefore 
not entirely efficient. This might either be due to suboptimal run conditions and thus be 
corrected by altering these (different run time, better adjustment of the density), or the 
HDLs in lower fractions correspond to HDLs having slightly higher densities than the ones 
floated. HDL-populations in serum are inhomogeneous and vary with the amount of 
cholesterol and fatty acids bound; therefore, the collected top fraction might be devoid of 
certain HDL-subpopulations.  
 
In the SEC-shift assay, preincubation of C14-acylated peptides and HDL led to a relative weak 
binding (fig. 3.14). The C18-acylation conferred stronger binding, whereas a cholesteroylated 
peptide shifted completely in size. Preincubation of HSA, HDL and FITC-labeled preS/2-
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48myristoyl led to binding of the peptide to HSA, no binding to HDL could be detected (data not 
shown). As the fishing assay was performed with a myristoylated CL-peptide, there is a 
discrepancy between these two results. The reason for this can be found in the technical 
differences between the two assays. As the crosslinker-assay leads to formation of covalent 
bonds between the interaction partners, the formed complexes are very stable. SEC on the 
other hand was performed under native conditions; the runs were performed in the same 
buffer as the preincubation. Therefore, the binding depended purely on the hydrophobic 
interactions between HSA and peptide or HDL and peptide, respectively. As hydrophobic 
interactions are weaker than covalent bonds, these  are more likely to dissociate. This again 
argues for the HSA-peptide interaction being stronger than the HDL-peptide interaction. 
 
4.1.7 Apolipoproteins, HCV and HBV 
Another virus replicating in the liver, the hepatitis C virus 2, depends heavily on its 
interaction with lipoproteins 2. HCV is a single strand RNA virus, it belongs to the family of 
Flaviviridae and forms the only representative of the genus Hepacivirus.  
HCV particles have been found to be associated with very low density lipoproteins and low 
density lipoproteins 118 and depend on the secretion of these for their particle formation 156. 
HCV particles from serum of chronically infected patients were found in VLDL-fractions; viral 
peak fractions were rich in apolipoprotein B100. Also, HCV particles from serum subjected to 
density gradient centrifugation showed a large variation in their density 118, 157, 157, 158. 
Furthermore, one of the receptors HCV requires for entry into hepatocytes is the 
lipoprotein-receptor scavenger receptor B1 (SRB1) 159. HCV therefore exploits a physiological 
metabolism pathway not only for particle formation but also for infection. 
Such lipoprotein associations have not been reported for HBV. Purification of HBV from 
human serum does not lead to copurification of apolipoproteins (S. Seitz, unpublished data); 
In sucrose density gradients, purified HBV particles run as one sharp peak in a high density 
fraction 160, lipoproteins are likely to run in lower density fractions.  
Mehdi and colleagues reported binding of Apolipoprotein H to recombinant HBsAg 161. They 
reported a specific, preS-independent interaction and speculated about a possible role for 
HBV-entry via the LDL-receptor on hepatocytes. This binding was later described to be 
enhanced after anti-Apo H antibody-binding to the ApoH 162. In our hands, ApoH had no 
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effect on HBV infection, nor did an ApoH overexpressing cell line show enhanced 
susceptibility (A. Schulze, unpublished data). Since no further reports on ApoH playing a role 
in HBV infection were published, this molecule is unlikely to play a role.  
Taken together, it has not been shown so far that HBV associates to lipoproteins or requires 
an interaction with lipoproteins for successful infection.  
 
4.1.8 Does the peptide-HDL interaction play a role in liver tropism or peptide binding to 
hepatocytes? 
The finding that HBV preS1 peptides bind ApoA1 raised the question whether HDLs play a 
role in hepatocyte binding by preS-peptides or in HBV entry itself. HDLs are normally taken 
up into hepatocytes by interaction of the apolipoprotein A1 with the scavenger receptor B1 
(SRB1) 163. A possible role of ApoA1 in mediating peptide or virus uptake into hepatocytes via 
this receptor could be imagined.  
Biodistribution was not altered in a mouse deficient for ApoA1 (fig. 3.16), nor could an 
influence of HDLs onto peptide binding to hepatocytes be detected (fig. 3.15); addition of 
purified HDLs to peptide on primary mouse hepatocytes did not lead to a significant increase 
or decrease in binding. HBV-infection showed a slight decrease in the presence of HDLs, yet 
no convincing evidence could be obtained. The HDL-concentration used here was under the 
physiological concentration, addition of higher amounts of HDLs might give further 
indications. 
Cholesteroylated peptides bound HDLs better than acylated peptides (fig. 3.14). 
Interestingly, biodistribution of a cholesteroylated peptide in mice differs from that of 
myristoylated or stearoylated peptide; almost no liver tropism is detectable, the peptide is 
rapidly excreted from the body 63. Also, liver tropism of the peptide was not impaired in an 
ApoA1 deficient mouse (fig. 3.16); rather, a slightly increased signal in the liver of the ApoA1 
deficient animal was found. It is therefore possible that peptide binding to HDLs inhibits 
dissociation of the peptide in the liver and retains it in the blood.  
A cholesteroylated peptide showed no difference in its infection inhibition behaviour (A. 
Schulze, unpublished data). This confirms the role of the N-terminal acylation as being 
merely an anchoring to the plasma membrane and that hepatocyte binding is independent 
of the liver targeting. 
Discussion 
 
 
97 
  
In summary, it could be shown that HSA and HDL bind HBV preS peptides depending on the 
N-terminal acylation and independent on the intactness of the site necessary for infection 
inhibition and hepatocyte binding. These interactions are likely to fulfill only a stabilizing 
function, preventing renal excretion or even protease degradation in the serum.  
 
4.2 Attempts to identify cellular interaction partners for HBV preS-peptides 
Since the crosslinker-peptides could be used to identify interaction partners for HBV preS-
peptides in serum, it was assessed whether they would allow a similar procedure on 
hepatocytes. These peptides have been shown to bind in a saturable , competable way to a 
cytoskeleton-linked protein on the plasma membrane of primary rat hepatocytes, arguing 
for a proteinacious receptor molecule 64. Therefore, these cells were used in a crosslinker-
assay in order to identify this protein. 
Cells were incubated with wt CL-peptide or variations thereof, lysed and subjected to affinity 
chromatography (fig. 3.18/3.19).Although differences were observed in the elution profiles, 
no cellular protein could be identified as specific interaction partner. Western blot analysis 
of the elution profiles showed a wt-specific band at a low molecular weight (15kDa, fig. 
3.20). Mass spectrometry of this band did not yield any results.  
A possible explanation for the failure of this assay might be the high reactivity of the aryl 
azide moiety. This molecule is known to react off unspecifically even in the dark, since it 
forms highly reactive nitrenes. Insertion of the peptides´ fatty acid into the hepatocyte 
membrane might have led to crosslinking to membrane lipids. Attempts to extract lipids 
from the elution fractions by methanol-chloroform-extraction, however, did not look 
promising. Also, if the peptide shows an initial attachment to heparane sulfate proteoglycans 
as it has been described for HBV 39, this assay would probably lead to peptide-proteoglycan-
complexes that would not be detected in western blot.  
 
4.3 Membrane activity of HBV preS-derived peptides 
In this work, preS-peptides have been shown to disturb membranes of phospholipid-
liposomes in a concentration-dependent manner (fig. 3.22). This membrane activity depends 
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on the intact sequence of the peptide (fig. 3.23); a replacement of five amino acids in the 
essential site by their respective D-enantiomers led to complete abrogation of the 
membrane activity. Non-acylated peptides were also defective in membrane disruption (fig. 
3.24). Deletions in the N-terminus proved to be tolerated up to amino acid 7, further 
deletion reduced membrane activity. Addition of the 11 amino acids from genotype B led to 
a marked increase in this function (fig. 3.24).  
Increasing fatty acid-chain length had a positive effect on the leakage; while neither a C5- 
nor a C8-acylation led to measurable membrane disruption, a C14-acylated peptide was 
active, a C18-acylated peptide even more so (fig. 3.25/3.26). C18-acylated peptides with a 
consensus sequence from the different HBV-genotypes proved to be more efficient than a 
genotype D peptide (fig. 3.26). Furthermore, the preS-peptides were found to associate 
tightly to phospholipids membranes in an acylation-dependent manner (fig. 3.27) and to 
disrupt these in an acylation- and sequence-dependent manner (fig. 3.28). 
In all points, these peptides show coherence in their requirements for membrane activity 
with the features required in Dane-particles for HBV-infectivity 62,42,28,20. Two discrepancies 
could be observed. First, peptides carrying the additional 11 aa of genotype B are slightly less 
active in infection inhibtion 62 but show a marked increase in membrane activity. Second, 
peptides where the N-terminal 6 amino acids are deleted show a drop in infection inhibition 
62 while their membrane activity is not altered. This suggests that the HBV pres1 N-terminus 
plays a role in viral membrane fusion that independent from the peptide´s inhibitory activity. 
For such a step, viral proteins often exhibit fusion peptides that adapt a secondary structure 
only when exposed to a certain trigger (introduction chapter 1.4.2). So far, no secondary 
structure of the HBV preS1 N-terminus has been reported. Chi and colleagues found pre-
structured motifs in the HBV preS1 sequence; they analyzed recombinantly expressed preS -
11-108 by nuclear magnetic resonance 164 164 and found "pre-structured domains" 
comprising amino acids 1-9, 11-14, 16-33 and 26-29 165. Also, secondary structure for the aa 
2-20 was determined by NMR, but only when peptides were held in a detergent milieu 
(personal communication S. Urban). A schematic representation of this structure is given in 
fig. 4.1 A. This structure consists of an alpha-helix spanning aa2-8, followed by a loop that 
spans aa 8-18 and contains several hydrophobic residues, and another alpha-helix. A lateral 
insertion of this helix into a phospholipid membrane as in fig. 4.1. B would be possible; the 
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more hydrophilic alpha-helices would interact with the more hydrophobic heads of the 
phospholipids, the loop would insert itself into the membrane.  
 
 
 
Fig. 4.1: Predicted model of the secondary structure of the HBV preS-peptide 2-22 in detergent milieu.  
A: Schematic drawing of the predicted peptide secondary structure.  
B: Model of the peptide insertion into a phospholipid membrane. The green line represents the N-terminal 
acylation; alpha-helices are depicted in blue, the loop structure in orange. Phospholipid heads are depicted in 
yellow, their lipid tail in black. Numbers of amino acids are indicated. Model of data from S. Urban/ B. Simon. 
 
The above model can be used to explain the differences observed in membrane activity. The 
Acylation of a minimal length is required for attachment to the target membrane. The 
domains spanning aa2-8 and 16-22 form helices that lie laterally in the target membrane; 
the additional 11 aa of genotype B, although their structure in a membrane environment is 
unknown, might stabilize this lateral insertion. Deletions ahead of the loop formed by aa8-16 
do not affect the membrane destabilization. Alterations in the loop are deleterious; 
replacement of these hydrophobic residues would strongly affect the ability to insert itself 
into a hydrophobic environment. 
Taken together, the findings of this work suggest that the HBV preS1 is an intrinsically 
unstructured domain that adopts its conformation at the host membrane. After interaction 
of preS with a specific receptor protein, the N-terminal myristoylation would confer 
association to the target membrane, followed by formation of a secondary structure in the 
preS1-N-terminus; this might be induced by contact to phospholipids. This part would then 
insert itself into the host membrane and destabilize it. The N-terminal acylation would 
primarily serve as membrane targeting signal 135, the correct sequence being essential. An 
exposure of the myristoyl-moiety only after a primary attachment to the host cell, a so-
called "myristoyl-switch", is possible. The HBV preS1-domain might therefore be a viral 
fusion peptide that plays a role during viral entry.  
 
4.4 Primary hepatocytes from other species are susceptible to HBV and HDV 
A B 
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The results of infection experiments on primary hepatocytes from different species and of 
published data concerning HBV or HDV infection of other species are summarized in table 
4.1. Rat hepatocytes were suceptible neither to HBV (fig. 3.30/3.31) nor to HDV (fig. 3.36). 
Rabbit hepatocytes could not be infected with HBV (fig. 3.30/3.32) but were susceptible to 
HDV infection (fig. 3.37). Both hamster and guinea pig hepatocytes were susceptible to HBV 
infection (fig. 3.33/3.34); in hamster cells, but not in guinea pig cells, infection could be 
inhibited with the preS-peptide. Neither hamster hepatocytes nor guinea pig hepatocytes 
were susceptible to HDV (3.37). 
All primary hepatocytes were susceptible to WHDV; in none of these cells could WHDV 
infection be inhibited by addition of the preS-peptide.  
 
It is not exactly known what step in viral entry is responsible for the restricted host range in 
HBV; several findings suggest that restriction happens early. For one, transfection of mouse 
hepatocytes, which are known to be not susceptible to HBV infection, with the HBV-genome 
leads to production of infectious virus 166. Transgenic mice containing the HBV genome were 
also shown to sustain replication of the virus 167. Also, lipofection of HBV DNA containing 
capsids into non-susceptible hepatoma cells led to viral replication and virion formation 49. 
Therefore, the restriction in infection that leads to the narrow host range is likely to take 
place at an earlier step such as receptor binding, uptake or viral fusion. 
Only few other species have been shown to be susceptible to HBV and /or HDV. The tree 
shrew Tupaia belangeri was shown to be susceptible to HBV-infection 168; infection could 
later be shown to be inhibited by HBV preS-peptides 60. Tupaia hepatocytes have also been 
reported to be susceptible to HDV 169; no infection inhibition has been reported. 
Woodchucks, who are susceptible to infection with woodchuck hepatitis virus (WHV) 170, are 
not susceptible to HBV infection but to HDV infection 128. A WHDV-infection has been shown 
on primary human hepatocytes 171. The phylogenetic relation of these species (fig. 4.1) 
shows that they are distributed over the superorder of euarchontoglires. Tupaias, the only 
small animal model susceptible to HBV known so far, belongs to the same grandorder 
(Euarchonta) as man; all species tested in this work belong to the other grandorder within 
the Euarchontoglires, the Glires. 
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Fig. 4.2: Phylogenetic relation of the superorder Euarchontoglires. Relations are shown as dendrogram; 
lengths of connective lines do not represent distances of relation. †: extinct order. (...): suborders and further 
branches not shown. (Data from: Animal Diversity Web)  
 
 
A summary of data from this work and from literature on the different infections is given in 
table 4.1.  
 
Tab. 4.1: Summary of species susceptibility to hepatitis B virus (HBV), hepatitis delta virus 
2
 
2
 and woodchuck 
hepatitis delta virus (WHDV). Species are indicated; +: infection or infection inhibition by preS-peptides 
detected. -.: no infection or infection inhibition by preS-peptides detected. nd: no data. blank field: if no 
infection is reported, no statement on inhibition is given.  
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Since the species analyzed in this work are more closely related to woodchucks than to 
primates, successful infection of hepatocytes from these animals with WHDV suggests a 
conserved receptor molecule for the WHV- L-protein within this grandorder (Glires). No 
detection of HDV antigen in hamsters, rats and guinea pigs is not due to a block of 
replication itself, since HDAg could be detected in the case of WHDV infection. The 
successful infection of rabbit hepatocytes, but not of hamster, rat or guinea pig hepatocytes 
with HDV suggests that the receptor for the HBV L-Protein is present in the Lagomorpha-
order but absent in the Rodentia-suborders of Myomorpha and Hystricomorpha. This theory 
is contradicted by infection of guinea pig- and hamster-hepatocytes by HBV observed in this 
work. As infection of primary guinea pig hepatocytes could not be inhibited by the preS1-
peptide, it could be argued that this is unspecific uptake, possibly caused by the high viral 
titre and the presence of Polyethylenglycol (PEG) which has been discussed as enhancer of 
unspecific uptake. Infection of primary hamster hepatocytes, however, was sensible to 
inhibition by the preS1-peptide, indicating specific receptor-mediated infection.  
It is possible that these species express a slightly altered receptor for the HBV L-protein that 
allows infection under the described conditions. The absence of viral spread during the 
course if the infection, which is usually observed when primary human hepatocytes are 
infected, suggests that the observed infection is rather inefficient and spread therefore not 
possible.  
Taken together, these data indicate that HBV entry and replication is possible in primary 
hepatocytes from species belonging to rather distant animal orders. If hamsters can be 
infected with HBV, these animals might be a useful small animal for the further study of HBV 
infection. 
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